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Abstract 
Application of Branching Double Annulation Cascade (BDAC) and Ring Opening 
Cyclization (ROC) Strategies: Access to Diverse fused Tetrahydroisoquinoline, 
Quinazolinone derivatives and Rutaecarpine Alkaloid 
  
         Nitrogen-containing compounds are the most common structural architectures in 
drug candidates, natural and biological products, and small-molecule therapeutics. N-
heterocyclic containing natural product synthesis has been a very challenging area due to 
the structural complexity inherent in these molecules. The nitrogen atoms contained in 
these molecules are essential for their biological activity, as nitrogen can hold a positive 
charge as well as act as both hydrogen-bond donor and hydrogen-bond acceptor. These 
features are significant for the interaction between medicinal agents and their molecular 
targets. Although synthetic chemists have long been fascinated by natural products, for 
the most part they have focused on developing the chemistry in order to make precise 
replicates of the compounds purified from natural sources. Recently, synthetic targets 
concerning natural products have not been limited to precise replication of the naturally 
occurring compounds.  
 
         The accumulation of insights and learning in total synthesis over the last few 
decades should enable organic chemists to “aim higher” to integrate natural products 
more closely with advance in biomedical research. Today, chemists can develop synthetic 
strategies to make both natural products and natural product-like compounds that are 
comparable to true natural products in size and complexity. The ability to synthesize in 
vitro complex natural products, combined with strategy of diversity-oriented synthesis 
(DOS) of natural product-like molecules, which allows very large numbers of natural 
product-based compound libraries to be made quickly, has made it possible for chemists 
to accelerate evolution in vitro in this process. Herein, we report a novel BDAC strategy 
for rapid access to diverse molecular library containing unprecedented THIQ fused 
skeletons by using 2-(2-bromoethyl)benzaldehyde 19 as a common substrate and variety 
of N,C-, N,O- and N,N-1,5-bisnucleophiles as SBAs. Apart from that we also successfully 
developed a facile methodology for Copper-catalyzed intramolecular α-C‒H amination 
via ring-opening cyclization strategy to quinazolin-4-one derivatives and application in 
Rutaecarpine synthesis. 
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PROPOSED CONTENTS OF THE THESIS:  
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Chapter II: Scaffold diversity through a branching double annulation cascade 
strategy: An iminium induced one-pot synthesis of diverse fused 
tetrahydroisoquinoline (THIQ) scaffolds. 
Chapter III: Copper-catalyzed intramolecular α-C‒H amination via ring-opening 
cyclization strategy to quinazolin-4-ones: development and application in 
Rutaecarpine synthesis. 
 
Chapter I: Introduction  
Nitrogen-containing compounds are the most common structural architectures in 
drug candidates, natural and biological products, and small-molecule therapeutics. N-
heterocyclic containing natural product synthesis has been a very challenging area due to 
the structural complexity inherent in these molecules. The nitrogen atoms contained in 
these molecules are essential for their biological activity, as nitrogen can hold a positive 
charge as well as act as both hydrogen-bond donor and hydrogen-bond acceptor. These 
features are significant for the interaction between medicinal agents and their molecular 
targets. Although synthetic chemists have long been fascinated by natural products, for 
the most part they have focused on developing the chemistry in order to make precise 
replicates of the compounds purified from natural sources. Recently, synthetic targets 
concerning natural products have not been limited to precise replication of the naturally 
occurring compounds. The accumulation of insights and learning in total synthesis over 
the last few decades should enable organic chemists to “aim higher” to integrate natural 
products more closely with advance in biomedical research. Today, chemists can develop 
synthetic strategies to make both natural products and natural product-like compounds 
that are comparable to true natural products in size and complexity. The ability to 
synthesize in vitro complex natural products, combined with strategy of diversity-
oriented synthesis (DOS) of natural product-like molecules, which allows very large 
numbers of natural product-based compound libraries to be made quickly, has made it 
possible for chemists to accelerate evolution in vitro in this process.  
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Among six-membered benzoheterocycles, quinazolines and quinazolinones 
represent a ubiquitous class of compounds displaying a broad range of biological 
activities. The importance of quinazolines as medicinal agents has consequently inspired 
the development of various synthetic methods toward this class of compounds. Many 
conventional synthetic methods for the construction of quinazoline-based pre-activated 
substrates or multistep transformations have been reported. Transition metal-catalyzed 
transformations now serve as powerful tools for synthesizing these useful compounds. On 
the other hand, an increasing demand for clean, fast, efficient, and selective processes, 
has prompted utilization of readily available, less toxic, and inexpensive metal catalysts.  
 
Over the past decade, substantial research interest has been focused on developing 
selective C-hetero bond formation reactions through Cu-catalyzed cross-dehydrogenative 
coupling. In most of the cases, a tertiary amine has been used as one of the partners 
where a C-H bond next to the heteroatom has been activated. Despite the significant 
advances made in this greener side of the cross coupling chemistry, application of this 
strategy in intramolecular C-heteroatom bond formation to synthesize pharmaceutically 
important and synthetically challenging heterocycles is far less studied. In this context, 
we planned to study cross-dehydrogenative C-N bond formation involving an amide and 
aniline under an O2 atmosphere with a Cu catalyst. Formation of an iminiun ion from 
amide, which is essential to implement such a strategy, is challenging due to 
delocalization of the nitrogen lone pair to the carbonyl oxygen.   
 
Quinazolin-4-(3H)-one compounds constitute the key core units of many 
synthetic drugs and natural products, such as luotonin A has cytotoxicity toward human 
cancer lines, while bouchardatine occurs in the natural product Bouchardatia neurococca. 
Traditionally, quinazolin-4(3H)-ones are prepared by the oxidative condensation of o-
aminobenzamide with aldehydes or carboxylic acid derivatives under acidic or basic 
conditions.  
 
Herein, we disclose a copper (I) catalyzed synthesis of quinazolin-4(3H)-ones 
from isatoicanhydride opened by benzylamine followed by C-H functionalization C-N 
bond forming process that uses oxygen as the oxidant and KOtBu as base and generates 
xv 
 
CO2 and O2 are the direct waste products. During the course of these reactions, an 
iminium intermediate formed, which is subsequently trapped by an amine nucleophile.   
Chapter II: Scaffold diversity through a branching double annulation cascade 
strategy: An iminium induced one-pot synthesis of diverse fused 
tetrahydroisoquinoline (THIQ) scaffolds. 
 
 
In the chapter I1, we have described the synthesis of diverse fused tetrahydroisoquinoline 
(THIQ) scaffolds through a branching double annulation cascade strategy. A branching 
double annulation cascade (BDAC) strategy for diverse and complex fused THIQ 
scaffolds via a highly reactive iminium induced one-pot double cyclization sequence 
involving Pictet-Spengler type cyclization has been developed for the first time. The 
salient features of this protocol are direct and rapid access to unprecedented diverse 
fused THIQ skeletons, metal/catalyst free, cleaner reaction profile, good to excellent 
yields and convenient approach. This catalyst-free domino process facilitates the double 
annulation with variety of scaffold building agents via two C-N and one C-X (X = C, N, 
O) bonds formation in a single step, under uniform reaction conditions. Furthermore, we 
reveal an unusual dual BDAC sequence leading to N-N linked isoquinoline dimer. 
The pursuit of identification of new small molecule modulators for chemical 
genetics and drug discovery has led to synthesis of natural product based compounds, 
combinatorial synthesis of libraries1 and cascade strategies.2 Awestruck by the nature’s 
ability to create structurally and functionally diverse pre-validated natural product 
libraries from a limited pool of simple building blocks and the demand for compound 
libraries with structural complexity and stereo genic centers3 has led synthetic organic 
chemist to explore chemical space paradigm by taking the leads from natural products, 
which is highly challenging.4 To meet this challenge, diversity oriented synthesis (DOS) 
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has emerged as an important tool which entails efficient synthesis of skeletally, stereo 
chemically and functionally diverse libraries. DOS by employing folding/branching 
pathways, build/couple/pair (B/C/P) strategies, and structural variations in common 
substrates/building blocks and branching cascade approaches have successfully 
demonstrated in creating diverse molecular scaffolds, which serve as biological probes 
and potential leads for drug discovery.   
 
In connection with our broader interests in developing synthetic strategies for 
diverse and complex polyheterocycles involving cascade annulations in a one-pot 
manner, herein, we are pleased to disclose a cascade sequence involving a highly reactive 
iminium intermediate and further Pictet-Spengler type cyclization for accessing three 
dimensional privileged THIQ compounds as branching double annulation cascade 
(BDAC).  
 
Numerous strategies have been reported for the synthesis of THIQ such as 
Strecker lactamization/alkylations, allylation-lactamization cascade, Mukaiyama-
Mannich lactamization/ alkylations, 1,3-dipolar cycloaddition reaction of azomethine 
imine and Grignard as well as allyltrimethoxysilane addition to imine. Latest approaches 
to substituted THIQ involve metal catalyzed ortho C-H allylation/cyclization (Scheme 
1b), cross-dehydrogenative coupling (CDC) reactions and redox-neutral reactions. 
Recently, we have developed cascade strategies for the synthesis of THIQ in one-pot 
fashion. However, many of the previous reported approaches to construct complex THIQ 
derivatives often have limited skeletal diversity and require several steps, and hence there 
lies a need to develop efficient strategies for THIQ compounds. To address this 
challenge, we envisioned that the concept of branching cascade could be utilized, 
involving the reaction of a common substrate with different scaffold-building agents 
(SBAs). To the best of our knowledge the branching cascade pathway has not yet been 
reported for the synthesis of diverse and complex THIQ molecules. With this in mind, we 
have identified 2-(2-bromoethyl)benzaldehyde 19a as a common substrate to generate 
highly reactive and versatile iminium intermediate for further diversification with wide 
range of SBAs 35.  THIQ with a stereo genic center at the C1 position occupy an 
important place among natural and unnatural compounds possessing valuable biological 
activities and are precursors for synthesis of complex alkaloids.  
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Herein, we report a novel BDAC strategy for rapid access to diverse molecular 
library containing unprecedented THIQ fused skeletons by using 2-(2-
bromoethyl)benzaldehyde 19a as a common substrate and variety of N,C-, N,O- and N,N-
1,5-bisnucleophiles as SBAs. The synthesized molecules contain multiple privileged 
structures such as tetrahydroisoquinoline (coralydine I and (+) cripsin A II), 
benzothiadiazinedioxide (IDRA-21 III), imidazoquinoxaline (PPQ-102 IV), 
quinazolinone (rutaecapine V), pyrroloquinoxaline (VI) and tetrazolo[1,5-c]quinoxaline 
(VII), which form part of natural products and biological important molecules (Figure 1).    
 
 
 
Figure 1. Naturally occurring THIQ alkaloids and representative examples of bioactive 
molecules containing our privileged motifs.   
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Figure 2. Synthesis of various diverse fused tetrahydroisoquinoline compounds 3a-3ac 
through branching double annulation cascade (BDAC) strategy. 
 
 
 
a Reactions were performed in DCE (1mL) with 19 (0.23 mmol), 35 (0.23 mmol) at 90 oC for 30-
60 min.  b 35a-35g represent various N,C-, N,O- and N,N-1,5-bisnucleophiles as SBAs. 
c dr was 
determined by 1H NMR spectroscopy. 
xix 
 
 
 
Scheme 2. Scope of BDAC strategy with 2-aminobenzohydrazide (2h). 
 
 
 
Chapter III : Copper-catalyzed intramolecular α-C‒H amination via ring-opening 
cyclization strategy to quinazolin-4-ones: development and application in 
Rutaecarpine synthesis. 
 
 
 In this chapter III, a copper-catalysed intramolecular α-C‒H amination has been 
developed for the synthesis of quinazolin-4(3H)-one derivatives from commercially 
available isatoic anhydride besides primary and secondary benzyl amines via Ring-
Opening Cyclization (ROC) Strategy. This method shows good functional group 
tolerance and allow access to a range of 2-aryl, 2-alkyl and spiroquinazolinone 
xx 
 
derivatives. However 2-methyl quinazolin-4(3H)-one synthesized from 2-amino-N-
isopropylbenzamide by C‒C bond cleavage and N-benzyl-2-(methylamino)benzamide 
afforded 1-methyl-2-phenylquinazolin-4(1H)-one along with 2-aryl quinazolin-4(3H)-one 
derivatives by N‒C bond cleavage for aromatization. It is the first general method to 
construct the potentially useful 2-methyl quinazolin-4(3H)-one by copper-catalyzed 
intramolecular C‒H amination. And also this ROC strategy has been successfully applied 
to the synthesis of quinazolinone alkaloid Rutaecarpine. 
 
Quinazolinone is an important N–heterocyclic scaffold, as of their abundance in 
biologically active compounds and numerous natural products such as rutaecarpine, 
tryptanthrin, luotonin A, B, E and F and bio active compounds (Figure 1). Owing to the 
promising biological & medicinal activities including anticancer, anti-inflammatory, 
antibacterial, antihypertensive properties, synthetically quinazolinone scaffolds have been 
highly in demand and remains a challenge in organic synthesis.  The direct 
functionalization of C–H bonds of organic compounds has recently emerged as a diverse 
atom economic carbon–heteroatom (C–X) and carbon–carbon (C–C) bond formation. 
Several diverse C–H functionalization methodologies without prefunctionalization of the 
coupling partners have been widely developed in the past decades. Previously, we have 
employed N-incorporation strategy for the synthesis of quinoxalines via dual C(sp2)-H 
functionalization and also, in recent past reported on the direct cycloaminative approach 
to imidazole derivatives via dual C–H functionalization.  
 
Over the past three decades, considerable progress has been made in the 
development of methods to construct sp2 carbon–nitrogen (C–N) bonds using palladium, 
copper or nickel catalysis. However, formation of sp3 C–N bonds remains one of the 
major challenges in the field of cross-coupling chemistry. Recently, much attention has 
been focused towards the development of transition-metal catalyzed intramolecular C–H 
amination strategies to assemble N–Heterocyclic compounds. In most of the cases, a 
tertiary amine has been used as one of the partner whereas α-C‒H bond has been 
activated. In 2010, Maiti. D reported cross-dehydrogenative sp3 C‒O bond formation an 
iminium ion from amide to construct dihydro-oxazinone derivatives, and also recently he 
reported copper-catalysed C(sp3-H functionalization/cyclisation of 2-amino-N,N-
dialkylbezamides for the synthesis of 2,3-disubstituted-4(3H)-quinazolinone 
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derivatives.13b Application of this strategy in intramolecular C‒heteroatom bond 
formation to synthesize challenging hetero cycles and pharmaceutically important 
compounds is less studied. Newly established methodology leading to the natural 
products are high demand for modern organic synthesis. 
 
In this context, we are pleased to report intramolecular cross-dehydrogenative 
coupling C‒N bond formation under aerobic conditions for the synthesis of quinazolin-
4(3H)-ones from isatoic anhydride and amines (benzylic & aliphatic) with copper (I) 
catalyst via ring opening cyclisation (ROC) strategy (Scheme 1). During this process an 
iminium ion intermediate formation, which is subsequently trapped by an amine 
nucleophile. 
 
Rutaecarpine, as a kind of natural quinazolinecarboline alkaloids isolated from 
fruits of evodia rutaecarpa, a plant used for treatment of headache, cholera, dysentery in 
Chinese medicine. Due to the medicinal importance of this alkaloid, various synthetic 
routes have been developed. Recently Jieping Zhu et al. synthesized rutaecarpine and (+)-
evodiamine by a silver salt-catalyzed insertion of the isocyano group into the N-H bond 
of the tryptamine followed by in situ lactamization. Herein, we described the shorter 
route to rutaecarpine from isatoicanhydride and tryptoline via ROC strategy.    
 
 
 
Figure 1. Quinazolinone skeleton containing natural products. 
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Scheme 1. Our present strategy for the synthesis of quinazolinone derivatives.  
 
 
 
Scheme 3. Synthesis of Rutaecarpine 
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Nomenclature 
 
1,10-phen              1,10-Phenanthroline 
Å              Angstrom 
Ac              Acetyl 
AcOH              Acetic acid 
Ar              Aryl 
BDAC              Branching double annulation cascade 
Boc              tert-Butyloxycarbonyl 
Bpy              2,2’-Bipyridine 
br              Broad (spectral) 
℃              Degree Celsius 
CDC              Cross-Dehydrogenative Coupling 
CPD                         Carbon proton decoupling 
Cy              Cyclohexyl 
d              Doublet (spectral) 
DABCO              1,4-Diazabicyclo[2.2.2]octane 
DBU              1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE              1,2-Dichloroethene 
DCM              Dichloromethane 
dd              Doublet of doublet 
ddd              Doublet of doublet of doublet 
DMA              Dimethylacetamide 
DMF              Dimethylformamide 
DMSO              Dimethyl sulfoxide 
dppf              1,1'-Bis(diphenylphosphino)ferrocene 
dt               Doublet of triplet 
DTBP               Di-tert-butyl peroxide 
equiv.    Equivalent(s) 
Et    Ethyl 
EtOH    Ethanol 
xxiv 
 
EWG    Electron withdrawing group 
FTIR               Fourier transform infrared spectroscopy 
GC-MS              Gas chromatography–mass spectrometry 
h              Hour(s) 
HR-MS              High Resolution Mass Spectroscopy 
Hz              Hertz 
i-Pr              Isopropyl 
J              Coupling Constant (in NMR Spectroscopy) 
K              Kelvin (Temperature) 
m              Multiplet (spectral) 
mCPBA              meta-Chloroperoxybenzoic acid 
MCRs              Multicomponent reactions 
Me              Methyl 
MeCN              Acetonitrile 
MeOH              Methanol 
mg              Milligram 
MHz              Mega Hertz 
min              Minute(s) 
MIR-ATR              Mid infrared- Attenuated Total Reflectance 
mL              milliliter(s) 
mmol              Millimole(s) 
Mp               Melting point 
MS              Molecular sieves 
NR              No reaction 
n-Bu              n-Butyl 
NMR              Nuclear Magnetic Resonance 
Nu              Nucleophile 
o              Ortho 
ORTEP              Oak ridge thermal ellipsoid plot 
OTf              Triflate group 
P              Para 
Ph              Phenyl 
PivOH               Pivalic acid 
xxv 
 
ppm              Parts per million 
psi                         Pounds per square inch 
q              Quartet (spectral) 
R              Alkyl 
Rf              Retention factor 
rt              Room temperature 
s              Singlet (spectral) 
SF              Solvent-free 
SSMR              Solid-state melt reaction 
t              Triplet (spectral) 
TBHP              tert-Butyl hydroperoxide 
TBPB              tert-Butyl peroxybenzoate 
tBu              tert-Butyl 
Temp               Temperature 
TEMPO               2,2,6,6-tetramethylpiperidine 1-oxyl 
tert               tertiary 
TFA               Trifluoroacetic acid 
TFAA               Trifluoroacetic anhydride 
THF               Tetrahyrofuran 
THIQ                          Tetrahydroisoquinoline     Tetrahydroisoquinoline 
TLC               Thin layer chromatography 
TMEDA               N, N, N′, N′-Tetramethylethylenediamine 
TMS               Trimethylsilyl 
XRD               X-ray diffraction 
δ               Chemical shift in parts per million
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                                 CHAPTER I 
                                  
Introduction 
 
I. 1 Application of Heterocyclic compounds: 
Heterocyclic compounds, both naturally produced and synthetically derived, often 
display important biological activity. In fact, more than 67% of the compounds 
listed in the Comprehensive Medicinal Chemistry (CMC) database contain 
heterocyclic rings. Synthesis of complex heterocyclic compounds is very 
challenging and attractive area in the field of organic chemistry.1  
In heterocyclic derivatives Nitrogen-containing compounds are the most common 
structural architectures in drug candidates, natural and biological products, and 
small-molecule therapeutics.2 N-heterocyclic containing natural product synthesis 
has been a very interesting area due to the structural complexity inherent in these 
molecules. The nitrogen atoms contained in these molecules are essential for their 
biological activity, as nitrogen can hold a positive charge as well as act as both 
hydrogen-bond donor and hydrogen-bond acceptor.3 These features are significant 
for the interaction between medicinal agents and their molecular targets. 
Natural products have proven to be cherished sources for the identification of new 
drug candidates, and also as tools for medicinal chemistry research and chemical 
biology. In fact, if we have a tendency to trace back human history, several natural 
product have conjointly long been wont to treat numerous human disorders and 
distinguished by their drug-like properties.4 To date, thousands of bioactive 
compounds have been isolated from plants, microbes, marine invertebrates, and 
other sources. Consequently, these chemical structures are used by chemists as 
references to scan the range house for drug discovery efforts.5 In the marketplace 
2 
 
launched drugs are either natural products themselves or natural product-derived 
molecules.6 
I. 2. Diversity Oriented Synthesis: 
Historically, natural product synthesis has been a very challenging area due to the 
structural complexity inherent in these molecules. Although synthetic chemists have 
long been fascinated by natural products, for the most part they have focused on 
developing the chemistry in order to make precise replicates of the compounds 
purified from natural sources. Recently, synthetic targets concerning natural 
products have not been limited to precise replication of the naturally occurring 
compounds.7 The accumulation of insights and learning in total synthesis over the 
last few decades should enable organic chemists to “aim higher” to integrate natural 
products more closely with advance in biomedical research. Today, chemists can 
develop synthetic strategies to make both natural products and natural product-like 
compounds that are comparable to true natural products in size and complexity.8 
The ability to synthesize in vitro complex natural products, combined with strategy 
of diversity-oriented synthesis (DOS) of natural product-like molecules, which 
allows very large numbers of natural product-based compound libraries to be made 
quickly, has made it possible for chemists to accelerate evolution in vitro in this 
process.9  
DOS is aimed at the efficient synthesis of an assembly of structurally complex and 
diverse molecules, which are screened for their ability to modulate a biological 
pathway in cells or organisms, while not relation to any specific super molecule 
target.10 In other words, DOS is a means to identify simultaneously therapeutic 
protein targets and small molecules that can modulate the functions of these 
therapeutic targets.11  
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  Figure 1. General reaction pathways in Organic synthesis.   
As a strategy, DOS is based on forward-synthetic analysis to guide its library 
synthesis. DOS allows many structurally complex and diverse compounds to be 
prepared efficiently in a flexible and modular way for biological assays.12 Because 
compounds generated from DOS by altering stereochemistry and skeletal arrays 
would display diverse chemical information in three-dimensional space, screening 
of such compounds would likely generate more hits poised for optimization. 
Screening of these would generate more hits. It should be noted that DOS as a 
synthetic strategy was not originated specifically for natural product synthesis.13 Yet 
it goes without saying that the DOS approach can be used to generate analogs of 
natural products and thus enrich the life science discovery.14 Therefore, DOS can 
obviously maximize the value of natural products in biomedical research by 
addressing unfavourable features of natural products.15 For instance, natural 
products tend to modulate biological targets that have general functions, but do not 
seem to modulate more specialized targets and processes. This challenge can 
perhaps be tackled by means of DOS.16   
I. 3. Importance of Tetrahydroisoquinoline:  
Tetrahydroisoquinoline (THIQ) is one of the most useful starting materials for the 
synthesis of heterocyclic scaffolds and bioactive compounds. The literature reveals 
several attempts for the synthesis of THIQs via iminium formation and further 
addition of various nucleophiles. The routes include 1,3-dipolar cycloaddition of 
azomethine imines, Grignard as well as allyltrimethoxysilane addition to imine, 
asymmetric reduction of imines, Mukaiyama-Mannich lactamization/ alkylations, 
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allylation-lactamization cascade and various multistep processes. Therefore, the 
application of iminium intermediate in other new type of reactions such as 
cycloadditions, atom insertions will make an important approach to this research 
field and is highly desirable.  
On the other hand, hybrid molecules embedded with different privileged scaffolds 
have long been attracted significantly due to their capability to enhance or modulate 
the biological properties of individual components.16 Isoquinolines, especially, 
1,2,3,4-tetrahydroisoquinolines 17 (THIQs I, II Figure 1).   
 
               Figure 2. Drug molecules with THIQ privileged structures. 
 
Figure 3. Various approaches to THIQ motifs starting from 2-(2-bomoethyl)benzaldehyde  
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In the recent times, a “branching cascade” has been proposed as a new technique of 
“Diversity Oriented synthesis” for the systematic exploration of chemical space.17 
Recently, we introduced the Branching Double Annulation Cascade (BDAC) as a 
new technique for accessing a series of multifunctional polyheterocyclic scaffolds in 
an efficient manner.  
As part of our ongoing interest in cascade cyclization,18 we assumed that a 
common type of starting material (X) would react with several bisnucleophiles 
(scaffold building agents, SBAs). Unlike our previous report, a major concern was 
that X would react with the electron rich SBAs leading to the formation of 
electrophile incorporated SBAs which may further react with X creating a mixture 
of products. The products formed have propensity to react again with electrophiles 
and therefore the overall process can be considered as complicated as it would be 
difficult to obtain any of the products in good yields. The challenge, therefore, was 
to search for a suitable starting material (X) and appropriate reaction conditions 
which should only give the desired product.  
 
 
At the outset of this study, our efforts were directed towards design and 
synthesis of different N,C-, N,O-, and N,N-1,5-bisnucleophiles With this pool of 
compounds in hand, a series of annulation reactions were envisaged in order to 
achieve skeletal diversity. Overall, it was found that the N,N-bisnucleophiles 
afforded excellent yields compared to N,C and N,O-bisnucleophiles, and 2-
aminobenzenesulfonamides (2f) though being weak nucleophile comparatively were 
the best among all 1,5-bisnucleophiles in terms of the reactivity and yield.  
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I. 4. Importance of Quinazolinones:  
 
Among six-membered benzoheterocycles,19 quinazolines20 and quinazolinones21 
represent a ubiquitous class of compounds displaying a broad range of biological 
activities. The importance of quinazolines as medicinal agents has consequently 
inspired the development of various synthetic methods toward this class of 
compounds. Many conventional synthetic methods for the construction of 
quinazoline-based pre-activated substrates or multistep transformations have been 
reported. Transition metal-catalyzed transformations now serve as powerful tools 
for synthesizing these useful compounds. On the other hand, an increasing demand 
for clean, fast, efficient, and selective processes, has prompted utilization of readily 
available, less toxic, and inexpensive metal catalysts.    
Over the past decade, substantial research interest has been focused on developing 
selective C-hetero bond formation reactions through Cu-catalyzed cross-
dehydrogenative coupling.22 In most of the cases, a tertiary amine has been used as 
one of the partners where a C-H bond next to the heteroatom has been activated.23 
Despite the significant advances made in this greener side of the cross coupling 
chemistry, application of this strategy in intramolecular C-heteroatom bond 
formation to synthesize pharmaceutically important and synthetically challenging 
heterocycles is far less studied.24 In this context, we planned to study cross-
dehydrogenative C-N bond formation under an O2 atmosphere with a Cu catalyst. 
Formation of an iminiun ion from amide, which is essential to implement such a 
strategy, is challenging due to delocalization of the nitrogen lone pair to the 
carbonyl oxygen.   
Quinazolin-4-(3H)-one compounds constitute the key core units of many synthetic 
drugs and natural products, represent a ubiquitous class of compounds displaying a 
broad range of biological activities.25 The importance of quinazolinones as 
medicinal agents has consequently inspired the development of various synthetic 
methods toward this class of compounds. Traditionally, quinazolin-4(3H)-ones are 
prepared by the oxidative condensation of o-aminobenzamide with aldehydes or 
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carboxylic acid derivatives under acidic or basic conditions.26 Many conventional 
synthetic methods for the construction of quinazolinone based substrates have been 
reported. Transition metal-catalyzed transformations now serve as powerful tools 
for synthesizing these useful compounds. On the other hand, an increasing demand 
for clean, fast, efficient, and selective processes, has prompted utilization of readily 
available, less toxic, and inexpensive metal catalysts.     
I. 5. C-H Functionalization: 
Herein, we disclose a copper (I) catalyzed synthesis of quinazolin-4(3H)-ones from 
isatoicanhydride opened by benzylamine followed by C-H functionalization C-N 
bond forming process that uses oxygen as the oxidant and KOtBu as base and 
generates CO2 and O2 are the direct waste products. During the course of these 
reactions, an iminium intermediate formed, which is subsequently trapped by an 
amine nucleophile. Recently, the use of Cu-catalyzed C-H functionalization 
reactions has gained significant traction, and a range of these methodologies relating 
to the construction of heterocycles have been successfully developed.27  
 
Figure 4. Intramolecular C-H functionalization. 
The current work is encompassed toward organic transformations involving 
iminium ion intermediate by controlling the reactivity toward distal C−H 
functionalization. However, the prevalent intramolecular C−H amination techniques 
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for synthesis of quinazolinones are centered on proximal C−H bond 
functionalization. Intramolecular oxidative C(sp3)−H amination is one of the most 
followed synthetic protocols toward N-heterocycle quinazolinone synthesis.28  
 
It is pleasant to mention that we also successfully developed a copper catalysed 
intramolecular α-C‒H amination for the synthesis of quinazolin-4(3H)-one 
derivatives from commercially available isatoic anhydride besides primary and 
secondary benzyl amines via Ring-Opening Cyclization (ROC) Strategy. This 
method, show good functional group tolerance and allow access to a range of 2-aryl, 
2-alkyl and spiro quinazolinone derivatives and also 2-methyl and 2-aryl quinazolin-
4(1H)-one derivatives by C‒C and N‒C bond cleavage in the progress of ROC 
strategy. It is the first general method to construct the potentially useful 2-methyl 
quinazolin-4(3H)-one by copper-catalyzed intramolecular C‒H amination. And also 
this ROC strategy has been successfully applied to the synthesis of quinazolinone 
alkaloid rutaecarpine. 
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CHAPTER II 
 
Scaffold Diversity through a Branching Double     
Annulation Cascade Strategy: An Iminium Induced 
One-pot Synthesis of Diverse Fused 
Tetrahydroisoquinoline (THIQ) Scaffolds 
 
II.1. INTRODUCTION: 
 
The pursuit of identification of new small molecule modulators for chemical 
genetics and drug discovery has led to synthesis of natural product based 
compounds, combinatorial synthesis of libraries1 and cascade strategies.2 Awestruck 
by the nature’s ability to create structurally and functionally diverse pre-validated 
natural product libraries from a limited pool of simple building blocks and the 
demand for compound libraries with structural complexity and stereo genic centers3 
has led synthetic organic chemist to explore chemical space paradigm by taking the 
leads from natural products, which is highly challenging.4 To meet this challenge, 
diversity oriented synthesis (DOS)5 has emerged as an important tool which entails 
efficient synthesis of skeletally, stereo chemically and functionally diverse 
libraries.6 DOS by employing folding7/branching pathways,8 build/couple/pair 
(B/C/P) strategies,9 structural variations in common substrates/building blocks10 and 
branching cascade approaches11 have successfully demonstrated in creating diverse 
molecular scaffolds, which serve as biological probes and potential leads for drug 
discovery. 
In connection with our broader interests in developing synthetic strategies for 
diverse and complex polyheterocycles involving cascade annulations12 in a one-pot 
manner, herein, we are pleased to disclose a cascade sequence involving a highly 
reactive iminium intermediate and further Pictet-Spengler13 type cyclization for 
accessing three dimensional privileged THIQ compounds as branching double 
annulation cascade (BDAC). 
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Numerous strategies have been reported for the synthesis of THIQ such as 
Strecker lactamization/alkylations,14 allylation-lactamization cascade, Mukaiyama-
Mannich lactamization/ alkylations, 1,3-dipolar cycloaddition reaction of 
azomethine imine15 and Grignard16 as well as allyltrimethoxysilane17 addition to 
imine as shown in Scheme 1a. Latest approaches to substituted THIQ involve metal 
catalyzed ortho C-H allylation/cyclization (Scheme 1b),18 cross-dehydrogenative 
coupling(CDC) reactions (Scheme 1c),19 and redox-neutral reactions.20 Recently, we 
have developed cascade strategies for the synthesis of THIQ in one-pot fashion.12c,d 
However, many of the previous reported approaches to construct complex THIQ 
derivatives often have limited skeletal diversity and require several steps, and hence 
there lies a need to develop efficient strategies for THIQ compounds. To address 
this challenge, we envisioned that the concept of branching cascade could be 
utilized, involving the reaction of a common substrate with different scaffold-
building agents (SBAs) and Scheme 1d illustrates the general concept of substrate-
based approach to scaffold diversity, which we have utilized in the present strategy. 
To the best of our knowledge the branching cascade pathway has not yet been 
reported for the synthesis of diverse and complex THIQ molecules. With this in 
mind, we have identified 2-(2-bromoethyl)benzaldehyde 19a as a common substrate 
to generate highly reactive and versatile iminium intermediate for further 
diversification with wide range of SBAs 35 (Scheme 1e).  THIQ with a stereo genic 
center at the C1 position occupy an important place among natural and unnatural 
compounds possessing valuable biological activities21 and are precursors for 
synthesis of complex alkaloids.   
 
II. 2. BACKGROUND:  
 
Owing to the importance of the tetrahydroisoquinolines (THIQs) and 
functionalized 2H-indazole skeletons several reactions have been reported for the 
synthesis of functionalized THIQ and indazoles. 
Various approaches for the synthesis of functionalized THIQs mainly fall 
into two general strategies via inter- or intramolecular nucleophilic addition to either 
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preformed precursor containing THIQ (Type A, Scheme 1)22 or addition to insitu 
generated of isoquinolinium salts (Type B, Scheme 1).23  
 
 
Scheme 1 
 
II. 2. 1. Selective Methods for functionalized THIQ (Type A): 
 
Among azomethine imine cycloaddition reaction several approaches have been 
developed which uses isoquinolium salts as 1,3-dipole for the cycloaddition with 
alkene giving rise to functionalized fused THIQs. For example, Guo and co-
workers24 have developed a [3+3] cycloaddition of Morita-Baylis- Hillman 
carbonates 2 with C,N-cyclic azomethine imines 1 for the synthesis of 
tetrahydropyridazinoisoquinoline derivatives 3 in good yields as shown in Scheme 
2.  
 
 
Scheme 2 
 
Similarly, several transformations involving reduction of isoquinolium imine, 
Grignard as well as trimethoxysilane addition to isoquinolium imine for the 
synthesis of functionalized THIQ have been reported. In 1996, Nayori et al.25 have 
reported the asymmetric reduction of isoquinolium imine 4 using ruthenium catalyst 
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for the synthesis of aliphatic/aromatic substituted THIQS 5 in excellent yields and 
high enantioselectivities (Scheme 3).  
 
 
Scheme 3 
 
In 2009, Al-Hiari et al.26 have disclosed the Grignard addition to isoquinolium 
imine 6 using aryl magnesium halide 7 with the help of 1,2-dibromoethane for the 
synthesis of benzyl substituted THIQS 8 (Scheme 4).  
 
 
Scheme 4 
Further, Itoh et al.27 have introduced the allyltrimethoxysilane 10 addition to 
isoquinolium imine 9 under chiral copper catalysis for the synthesis of allyl 
substituted THIQS 11 and the allyl adduct thus formed was transformed to (-)- 
emetine in good yields (Scheme 5).  
 
 
Scheme 5 
In recent years, several approaches involving redox-neutral annulation reactions 
as well as cross-dehydrogenative coupling (CDC) have been developed for the 
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synthesis of functionalized THIQs. In 2014, Seidel et al.28 have developed a 
complementary redox-Mannich reaction to the classic three component Mannich 
reaction which utilizes the same starting materials (THIQ 12, aldehyde 13 and 
ketone 14) but incorporates an isomerization step that enables the facile preparation 
of ring-substituted β-amino ketones 15 and occur under relatively mild conditions 
with the benzoic acid assistance (Scheme 6). 
 
 
Scheme 6 
 
In 2014, Kobayashi et al.29 have reported a copper/metal-free cross-
dehydrogenative (CDC) reaction of tertiary amines 16 with nitrostyrene 17 for the 
synthesis of functionalized THIQ 18 using a catalytic amount of sulfuryl chloride 
(SO2Cl2) under mild aerobic conditions. On the basis of the nature of SO2Cl2, it was 
assumed that the reagent acts as a radical initiator to induce the metal-free CDC 
reaction via a radical-initiated autoxidation mechanism.  (Scheme 7).   
 
 
Scheme 7 
 
II. 2. 2. Selective Methods for functionalized THIQ (Type B): 
 
In 2014, Singh et al.30a have reported a general and highly efficient Lewis acid 
catalyzed one-pot allyation/ lactamization cascade for the synthesis of diversely 
substituted tetrahydroisoquinolines 22. The cascade effects one C-C and two C-N 
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bond-forming events in one-pot and the product thus obtained was successfully used 
for the total synthesis of (±)-crispine A (Scheme 8). 
 
 
Scheme 8 
 
Further the same group30b simultaneously reported the novel and efficient 
synthesis of a variety of tetrahydroisoquinolines via a Lewis acid catalyzed domino 
Mukaiyama-Mannich lactamization/alkylation strategy. The compounds aldehyde 
19, enolate 23 and amine 20 react in a cascade one-pot fashion under zinc or copper 
triflate catalyst to afford substituted THIQ framework 24. This transformation 
comprises a sequential formation of three new bonds through a one-pot, three-
component procedure to afford product in moderate to high yields. The product thus 
generated was successfully used for a concise synthesis of (±)-homolaudanosine. 
(Scheme 9). 
 
 
 
Scheme 9 
 
In 2014 our group has31 developed a one-pot cascade reaction of aldehyde 19, 
aniline 25, isocyanide 26 and sodium azide 27 for the synthesis of triazole 
substituted THIQ 28 skeleton using Ugi-azide four-component reaction (Scheme 
10). 
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Scheme 10 
Recently, we have developed a three-component cyclic iminium induced one-
pot Groebke-Blackburn-Bienayme (GBB) double annulation cascade (DAC) for the 
synthesis of skeletally diverse DHIQ skeletons 3032 (Scheme 11).  
 
 
Scheme 11 
 
 
Scheme 12 
Recently, we have also developed a one-pot sequential multiple annulation 
cascade (SMAC) strategy for the synthesis of 2H-indazole fused tetrahydroiso-
quinolinoquinoxalines and tetrahydroisoquinolinodiazepines via 2H-indazole 
formation and subsequent intramolecular cyclic iminium formation, and C3-
functionalization of intermediate 2H-indazole (Scheme 13)33. 
 
The versatility of 2-(2-bromoethyl)benzaldehyde (19a) as a promising 
bifunctional reactant in various organic transformations has been well documented 
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by our group31-33 and others,30 especially leading to tetrahydroisoquinoline (THIQ) 
motifs based natural products and their analogues (Scheme 14).  
 
 
 
Herein, we report a novel BDAC strategy for rapid access to diverse 
molecular library containing unprecedented THIQ fused skeletons by using 2-(2-
bromoethyl)benzaldehyde 1a as a common substrate and variety of N,C-, N,O- and 
N,N-1,5-bisnucleophiles as SBAs. The synthesized molecules contain multiple 
privileged structures such as tetrahydroisoquinoline (coralydine I and (+) cripsin A 
II), imidazoquinoxaline (PPQ-102 III),34 pyrroloquinoxaline (IV),35 tetrazolo[1,5-
c]quinoxaline (V),36 quinazolinone (rutaecapine VI),37 and benzothiadiazinedioxide 
(IDRA-21 VII),38 which form part of natural products and biological important 
molecules (Figure 1).  
  
 
Figure 1. Naturally occurring THIQ alkaloids and representative examples of bioactive 
molecules containing our privileged motifs. 
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II. 3. Results and Discussion: 
 
        To this end, initially to check the feasibility of our branching cascade 
strategy we performed a model reaction of 2-(2-bromoethyl)benzaldehyde (19a) 
with 2-(2-aminophenyl)imidazole (35a) under polar protic solvents such as MeOH 
and EtOH at various temperatures (Table 1, entries 1-4), of which under reflux 
temperature in MeOH gave the desired product 36a albeit in 47% yield (Table 1, 
entry 2). Inspired by this result, in order to increase the yield further, we screened 
the reaction under polar aprotic solvents such as acetonitrile and 1,4 dioxane, which 
afforded the moderate yields of the products (20-53%, Table 1, entries 5-7). We 
continued our attempts to optimize the yield by performing the reaction in 
chlorinated solvents (Table 1, entries 8-10) and to our delight, DCE at reflux 
temperature provided the desired product in good yield (Table 1, entry10). After 
having screened various solvents, we have chosen DCE as a solvent for further 
optimization studies. The increase in reaction temperature to 90 oC resulted in better 
yield of the product 36a (75%) (Table 1, entry 11), however, further increase in 
temperature to 100 oC as well as the unconventional microwave heating could not 
improve the yield of the product further (Table 1, entries 12 and 13). Our attempts to 
use additives like DBU, PTSA and Et3N have failed to improve the yield of the 
product (Table 1, entries 14-16). Similarly, employing dehydrating agents like 4Å 
molecular sieves and Na2SO4 did not aid in enhancing the yields (Table 1, entries 17 
and 18).   
        At the outset of this study, our efforts were directed towards design and 
synthesis of different N,C-, N,O-, and N,N-1,5-bisnucleophiles (Figure 2). With this 
pool of compounds (35a-35h) in hand, a series of annulation reactions were 
envisaged in order to achieve skeletal diversity. With the standard reaction 
conditions in hand, we first subjected substituted imidazole based N,C-
bisnucleophiles 35a(I) and 35a(II) leading to corresponding products 36b and 36c in 
67% and 68% yields. In addition, we have also employed 2-(1H-pyrrol-1-yl)aniline 
(35b) in our cascade annulation resulting in pyrroloquinoxaline-THIQs (36d-36f) in 
good yields (71-73%). The fact that the more nucleophilic pyrrole substituted SBA 
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35b gave better yield than imidazole substituted SBA 35a is in agreement with our 
proposed concept. 
Table 1. Optimization conditions for the synthesis of fused Tetrahydroisoquinoline 
compound 3a through BDAC a 
 
Entry Solvent Additive Tempt oC Time (min) Yield (%)b 
1 MeOH - rt 120 45 
2 MeOH - reflux 60 47 
3 EtOH - rt 120 40 
4 EtOH - reflux 60 42 
5 CH3CN - rt 90 20 
6 CH3CN - reflux 60 53 
7 1,4-Dioxane - reflux 60 45 
8 DCM - rt 90 42 
9 DCE - rt 90 56 
10 DCE - reflux 60 66 
11 DCE - 90  30 75c 
12 DCE - 100  30 65 
13 DCE - 90  30 66d 
14 DCE DBU 90  60 0 
15 DCE PTSA 90  60 70 
16 DCE Et3N 90  60 68 
17 DCE M.S. 90  60 70e 
18 DCE Na2SO4 90  60 69 
 
a Reaction conditions: 19a (0.23 mmol), 35a (0.23 mmol) and 1 mL of solvent; b Isolated 
yields after column chromatography; c No detrimental effect observed on reaction outcome 
by varying the concentration of reaction. d Unconventional microwave heating was used;  e 
4Å molecular sieves was used. 
 
In our efforts to diversify the skeleton, we investigated azole based N,N-
bisnucleophiles such as 35c and 35d, which resulted in the corresponding products 
tetrazoloquinozalino-THIQs (36g-36i, 75-87%) and benzimidazoquinazolino-THIQs 
(36j and 36k, 48% and 65%). Tetrazole based SBA 35c was the best nucleophile, 
which afforded the excellent yields of the corresponding products among all 
heterocyclic SBAs. With an aim to functionally diversify the skeleton and for 
comparative study, we evaluated the reactivity of the amide as N,N-bisnucleophile, 
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in our present strategy. To our surprise the reaction of variety of 2-
aminobenzamides 35e with 19a-19c under standard conditions, afforded the 
corresponding products (36l-36s) in good to high yields (48-70%). It is to be noted 
that these products could be diversified further for various applications. The 
successful employment of 2-aminobenzamides 35e (I-V), prompted us to examine 
the 2-aminobenzenesulfonamides (35f) as a scaffold building agent for the synthesis 
of tetrahydrobenzothiadiazinoisoquinolino-6,6-dioxide which is a privileged 
scaffold present in several natural products of biological interest.39 Accordingly, 
when we have reacted variety of 2-aminosulphonamides (35f) with 19a-19c, 
afforded the products 36t-36z in good to excellent yields (62-90%).  
Encouraged by the results, we envisioned to explore the nucleophilicity of 
oxygen in our present strategy, by treatment of 2-aminobenzyl alcohol 35g(I) and 2-
aminobenzoic acid 35g(II) with 19a, which afforded 36aa and 36ab in 60 and 72% 
yields, respectively. Due to the ubiquity of THIQ based natural products containing 
C1 stereocenter, many research groups have focused on the introduction of a 
substituent at C1 position in a stereogenic fashion and also on natural products 
containing two contiguous and 1,3 stereocenters. Our aim to introduce 
stereochemical diversity in our present strategy, prompted us to examine the 
possibility of diastereoselectivity by employing the 1,3 stereocenter inducing SBAs. 
With this idea in mind, we selected the phenyl substituted secondary alcohol 
35g(III) as N,O-1,5 bisnucleophile, which afforded the expected product 36ac 
although in low stereoselectivity (cis/trans = 4:3) as a mixture of inseparable 
diastereomers in 52% yield. The relative configuration of the major diastereomers 
was assigned to be cis based on NOE experiment. Our attempts to improve the 
diastereoselectivity by varying temperature, solvent system and concentration went 
in vein. All the compounds were confirmed by 1H and 13C spectroscopy and high 
resolution mass spectrometry. Although, the NMR spectroscopic data support the 
formation of fused privileged tetrahydroisoquinoline scaffolds 36, the structures of 
36p and 36t were unambiguously secured by X-ray crystal analyses.  
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Figure 2. Synthesis of various diverse fused tetrahydroisoquinoline compounds 36a-
36ac through branching double annulation cascade (BDAC) strategy.  
 
 
 
 a Reactions were performed in DCE (1mL) with 19 (0.23 mmol), 35 (0.23 mmol) at 90 oC 
for 30-60 min.  b 35a-35g represent various  N,C-, N,O- and N,N-1,5-bisnucleophiles as 
SBAs. cdr was determined by 1H NMR spectroscopy. 
In our present BDAC strategy, several diverse halo-substituted compounds have 
been synthesized, which could be utilized as versatile synthons for further 
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diversification.  The present BDAC strategy was proved to be very general and 
versatile by enabling variety of SBAs with distinct nucleophilic centers to react with 
common precursor under unified reaction conditions. Overall, it was found that the 
N,N-bisnucleophiles afforded excellent yields compared to N,C and N,O-
bisnucleophiles, and 2-aminobenzenesulfonamides (35f) though being weak 
nucleophile comparatively were the best among all 1,5-bisnucleophiles in terms of 
the reactivity and yield. The substituents such as Me and Br on common substrate 1 
was non detrimental on reaction outcome and yield of the products (36a-36ac).  
      Scheme 13. Scope of BDAC strategy with 2-aminobenzohydrazide (35h). 
 
Further aiming to expand the diversity in the BDAC strategy, we envisioned that 
by using 2-aminobenzohydrazide (35h) as 1,6-bisnucleophile can result in 7-
membered fused tetrahydrobenzotriazepino isoquinolinone skeleton. To our 
surprise, when we used 2- aminobenzohydrazide (35h) as N,N-bisnucleophile, 
resulted in the dimer product 3ae instead of expected compound 36ad (Scheme 13), 
which was confirmed by spectral and X-ray crystal structure analyses. The 
formation of 36ae can be explained by dual BDAC reactions involving 
transamination of 35h with intermediate A with the elimination of hydrazine 
hydrobromide. 
 
 After having developed the BDAC strategy for the synthesis of diverse 
heterocyclic scaffolds, we envisaged that it would be appropriate to check the 
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scalability of our BDAC strategy for the synthesis of fused tetrahydroisoquinoline 
compounds 36. Accordingly, we performed the scale-up (1g scale) reaction for the 
synthesis of the product 36o, resulting in 0.79 gm, 56% yield (Figure 2).   
Based on the literature reports12c,d and experimental studies we have formulated 
a plausible reaction mechanism for the synthesis of diverse fused 
tetrahydroisoquinoline derivatives as shown in scheme 3. Initially, 2-(2-
bromoethyl)benzaldehydes (19a) and scaffold-building agents (SBAs) 35 react to 
give an imine intermediate I, followed by an intramolecular alkylative cyclization 
leading to reactive Mannich base II which on further Pictet-Spengler13 type 
annulation affords the desired product 36 (Scheme 14).    
 
Scheme 14. Plausible reaction mechanism for the synthesis of THIQ fused compound 
3.   
 
 
 
II. 4. Conclusion: 
        In summary, we have successfully developed an advanced metal-free double 
annulation branching cascade (BDAC) strategy for the synthesis of library of 29 
new, complex and diverse tetrahydroisoquinoline fused derivatives by using a 
variety of N,C-, N,O- and N,N-1,5-bisnucleophiles as a SBAs and 2-(2-
bromoethyl)benzaldehydes as a common precursor under uniform reaction 
conditions. The important features of the present protocol are metal and catalyst-
free, operational simplicity, use of simple starting materials and moderate to 
excellent yields. Moreover, the success of gram-scale synthesis of fused THIQ make 
this process useful for industrial applications. Undoubtedly, this protocol which 
affords three dimensional THIQ derivatives which are diverse in its coverage of 
chemical space, should prove useful for further scaffold innovation in drug 
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discovery program. Further, studies on enantioselective synthesis of these scaffolds 
are currently under way.   
   
II. 5. Experimental Section 
 
General Considerations 
 
     IR spectra were recorded on a FTIR spectrophotometer. 1H NMR spectra 
were recorded on 400 MHz spectrometer at 295 K in CDCl3; chemical shifts (δ 
ppm) and coupling constants (Hz) are reported in standard fashion with reference to 
either internal standard tetramethylsilane (TMS) (δH = 0.00 ppm) or CHCl3 (δH = 
7.25 ppm). 13C NMR spectra were recorded on 100 MHz spectrometer at RT in 
CDCl3; chemical shifts (δ ppm) are reported relative to CHCl3 [δC = 77.00 ppm 
(central line of triplet)]. In the 1HNMR, the following abbreviations were used 
throughout: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, m = 
multiplet and br s. = broad singlet. The assignments of signals were confirmed by 
1H, 13C, and DEPT spectra. High-resolution mass spectra (HR-MS) were recorded 
using Q-TOF multimode source.  Melting points were determined on an electro 
thermal melting point apparatus and are uncorrected. 2-(2-bromoethyl)benzaldehyde 
(19a-19c) were prepared by using known procedures. All the bisnucleophiles such 
as N,C-, N,O- and N,N-1,5-bisnucleophiles as a SBAs (35a-35h) which were either 
prepared in the laboratory or purchased from commercial sources. All the dry 
solvents such as, MeOH, EtOH and 1,4-Dioxane were dried over sodium metal and  
CH3CN, DCM and DCE were dried over calcium hydride. 
All small scale dry reactions were carried out using standard syringe-septum 
technique. Reactions were monitored by TLC on silica gel using a combination of 
petroleum ether and ethyl acetate as eluents. Reactions were generally run under 
argon atmosphere. Solvents were distilled prior to use; petroleum ether with a 
boiling range of 40 to 60 ˚C was used.  
 
(I) General Procedure 1: Preparation of isochromans40 
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A mixture of the substituted phenylethyl alcohol (i) (4.97 mmol), 
chloromethylmethyl ether (7.046 mmol) and N,N-diisopropylethylamine (9.95 
mmol)  in dry dichloromethane (15 mL)  was stirred under nitrogen atmosphere for 
2.5 h at rt. The reaction mixture was then washed with water, dried (Na2SO4) and 
the solvent was removed in vaccuo.  The crude MOM acetal (ii) was dissolved in 
dried acetonitrile and added to cooled (0 oC) solution of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) (4.97 mmol).  The reaction was carried out 
under nitrogen atmosphere for 3h. Then the mixture was quenched by the addition 
of l M NaHCO3.  The organic phase was washed with brine, dried with anhydrous 
sodium sulphate and evaporated under reduced pressure. Purification by column 
chromatography afforded corresponding substituted isochromans.  
 
(II) General procedure 2: Preparation of 2-(2-bromoethyl)benzaldehydes (19a-
19c)40  
 
      To a solution of the substituted isochroman iii (7.46 mmol) derivatives in 
acetonitrile (15 mL), CuBr2 (8.95 mmol) was added under nitrogen atmosphere. The 
solution was refluxed for about 2h and then cooled to room temperature.  The 
reaction mixture was added water, extracted with ethyl acetate.  The combined 
organic extracts were washed with brine and dried with anhydrous Na2SO4, filtered 
and concentrated and then purified by silica gel column chromatography to afford 
the products (19a-19c) in 68-74% yield. 
27 
 
(III) General procedure 3: Synthesis of diverse scaffold containing fused 
tetrahydroisoquinolines (36a-36ae) through BDAC strategy: 2-(2-
Bromoethyl)benzaldehydes (19a-c) (50 mg, 0.23 mmol) and variety of 
bisnucleophiles 35 (0.23 mmol) were taken in a 5 mL round bottom flask and added 
1 mL of DCE heated at 90 oC. After completion of the reaction (monitored by TLC), 
the DCE solvent was completely evaporated under reduced pressure. The reaction 
mixture was quenched by aq. NaHCO3 and extracted with ethyl acetate (2 × 20 mL). 
The combined organic layer was washed with brine solution and allowed to dry over 
anhydrous Na2SO4. The crude extract was purified by filtration through a silica gel 
(100-200 mesh) column using hexane and ethyl acetate as eluents to yield the 
desired product 36a-36ae.    
(IV) General procedure 4: Large scale synthesis of isoquinolinoquinazolinone 
36o through BDAC strategy.  
2-(2-Bromoethyl)benzaldehyde (1a) (1000 mg, 4.69 mmol) and N,N-bisnucleophile 
35e(IV) (790 mg, 4.69 mmol) were taken in a 25 mL round bottom flask and added 
10 mL of DCE heated at 90 oC. After completion of the reaction (monitored by 
TLC), the DCE solvent was completely evaporated under reduced pressure. The 
reaction mixture was quenched by aq. NaHCO3 and extracted with ethyl acetate (2 × 
20 mL). The combined organic layer was washed with brine solution and allowed to 
dry over anhydrous Na2SO4.  The crude extract was purified by filtration through a 
silica gel (100-200 mesh) column using hexane and ethyl acetate as eluents to yield 
the desired product 36o in 56%, 790 mg. 
Spectroscopic data of all unknown compounds:  
 7,11b-Dihydro-6H-imidazo-6H-imidazo[1,5-a]isoquinolino[1,2-c]quinoxaline 
(36a): 
 Physical State :Brown solid  
 Yield  :46 mg, 72% 
Mp  :198−200 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3112, 2923, 2854, 1710, 
1600, 1507, 1462, 1351, 1109, 746, 653;  
 1H NMR (400 MHz, CDCl3) δ ppm = 2.86 (d, J = 16.1 Hz, 1H), 3.21−3.28 (m, 1H), 
3.36−3.40 (m, 1H), 3.97 (ddd, Ja = 12.5, Jb = 5.4 and Jc = 2.2 Hz, 1H), 5.53 (s, 1H), 
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6.92−6.97 (m, 2H), 7.05 (d, J = 7.8 Hz, 1H), 7.17−7.23 (m, 4H), 7.26−7.32 (m, 1H), 7.43 
(dd, Ja = 7.8 and Jb = 1 Hz, 1H), 8.0 (s, 1H);  
 13C NMR (100 MHz, CDCl3) δ ppm = 27.1, 43.7, 54.7, 114.7, 115.7, 119.7, 124.6, 124.7, 
126.3, 126.9, 127.4, 127.52, 129.3, 131.5, 133.1, 133.9, 137.6;  
 HR-MS (ESI+) m/z calculated for C18H16N3+ = [M+H+]: 274.1339; found: 274.1326. 
2-Methyl-7,11b-dihydro-6H-imidazo[1,5-
a]isoquinolino[1,2-c]quinoxaline (36b):  
Physical State   :Brown solid 
Yield   :45 mg, 67%  
Mp    :177−180 oC 
IR (MIR-ATR, 4000−600 cm-1): νmax = 3055, 2924, 2858, 1705, 1513, 1360, 816, 736, 651; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 2.32 (s, 3H), 2.82−2.87 (m, 1H), 3.19−3.24 (m, 1H), 
3.28−  3.35 (m, 1H), 3.87−3.92 (m, 1H), 5.45 (s, 1H), 6.94−6.96 (m, 2H), 7.01 (d, J = 1.5 
Hz, 1H), 7.13−7.16 (m, 1H), 7.19−7.22 (m, 2H), 7.24−7.25 (m, 1H), 7.30−7.33 (m, 1H), 
7.97 (d, J = 1 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 20.7, 27.1, 43.9, 54.9, 115.2, 116.3, 124.7, 124.8, 
126.2, 126.9, 127.3, 127.4, 127.7, 129.3, 129.8, 131.5, 133.1, 134.0, 135.4; 
  
 HR-MS (ESI+) m/z calculated for C19H18N3+ = [M+H+]: 288.1495; found: 288.1482. 
   
 10-Bromo-7,11b-dihydro-6H-imidazo[1,5-a]isoquinolino[1,2-c]quinoxaline (36c):  
 Physical State   :Brown solid 
  Yield   :56 mg, 68%  
 Mp   :168−170 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3049, 2922, 1718, 
1604, 1509, 1475, 1347, 1273, 813, 739, 651;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.78−2.82 (m, 1H), 3.2 (ddd, Ja = 16.9, Jb = 11.5 and 
Jc = 5.9 Hz, 1H), 3.42 (ddd, Ja = 13.2, Jb = 11.7 and Jc = 4.4 Hz, 1H), 4.02−4.07 (m, 1H), 
5.56 (s, 1H), 6.92 (td, Ja = 7.7 and Jb = 1.2 Hz, 1H), 7.00−7.05 (m, 3H), 7.17−7.20 (m, 1H), 
7.32 (dd, Ja = 8.3 and Jb = 1.5 Hz, 1H), 7.41−7.45 (m, 2H), 8.03 (d, J = 1 Hz, 1H); 
  13C NMR (100 MHz, CDCl3) δ ppm = 25.8, 43.9, 54.6, 114.8, 115.8, 119.8, 119.9, 124.4, 
125.2, 126.1, 127.0, 129.7, 130.6, 131.0, 131.7, 132.9, 135.8, 136.7; 
 HR-MS (ESI+) m/z calculated for C18H15BrN3+ = [M+H+]: 352.0444; found: 352.0430. 
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7,11b-Dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-
c]quinoxaline (36d): 
Physical State   :Brown solid  
Yield   :45 mg, 71%  
Mp    :120−122 oC 
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3052, 2902, 2829, 1506, 1337, 1288, 1221, 738, 701, 
643; 
 1H NMR (400 MHz, CDCl3) δ ppm = 2.8 (d, J = 16.1 Hz, 1H), 3.19−3.27 (m, 1H), 
3.31−3.38 (m, 1H), 3.90−3.95 (m, 1H), 5.46 (s, 1H), 6.07−6.08 (m, 1H), 6.32−6.34 (m, 1H), 
6.84−6.88 (m, 1H), 6.97−6.99 (m, 1H), 7.05−7.20 (m, 5H), 7.31−7.34 (m, 2H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 27.1, 44.0, 56.2, 105.7, 110.0, 114.5, 115.1, 115.1, 
119.7, 125.0, 126.0, 127.0, 127.5, 127.7, 128.5, 129.2, 134.2, 134.4, 137.6; 
  
HR-MS (ESI+) m/z calculated for C19H17N2+ = [M+H+]: 273.1386; found: 273.1382. 
 10-Methyl-7,11b-dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-c]quinoxaline (36e):  
 Physical State :Brown solid  
 Yield: 38 mg, 60%  
 Mp 130−132 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3044, 2918, 2847, 
1505, 1337, 1289, 1164, 741, 701, 610, 549; 
 1H NMR (400 MHz, CDCl3) δ ppm = 2.29 (s, 3H), 2.78 (d, J = 15.7 Hz, 1H), 3.17−3.25 (m, 
1H), 3.34 (td, Ja = 12 and Jb = 3.9 Hz, 1H), 3.9−3.96 (m, 1H), 5.44 (s, 1H), 6.09 (d, J = 2.9 
Hz, 1H), 6.34 (t, J = 3.2 Hz, 1H), 6.85−6.89 (m, 1H), 6.98−7.03 (m, 2H), 7.05−7.09 (m, 
1H), 7.14 (s, 1H), 7.17 (dd, Ja = 2.7 and Jb = 1.7 Hz, 1H), 7.23 (s, 1H), 7.33 (dd, J = 7.8 Hz, 
1H). 
   
13C NMR (100 MHz, CDCl3) δ ppm = 21.3, 26.6, 44.1, 56.14, 105.7, 110.0, 114.4, 115.0, 
115.1, 119.6, 124.9, 127.6, 127.8, 128.5, 129.0, 131.0, 134.1, 135.5, 137.6; 
  
  HR-MS (ESI+) m/z calculated for C20H19N2+ = [M+H+]: 287.1543; found: 287.1539. 
  10-Bromo-7,11b-dihydro-6H-isoquinolino[2,1-a]pyrrolo[2,1-c]quinoxaline (36f):  
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 Physical State   :Brown solid  
 Yield   :44 mg, 73%  
 Mp.    :148−150 oC 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3048, 2919, 2833, 1508, 1340, 1165, 741, 703, 657, 
538;  
 1H NMR (400 MHz, CDCl3) δ ppm =  2.75 (d, J = 17.6, 1H), 3.16−3.24 (m, 1H), 3.38 (ddd, 
Ja = 13.1, Jb = 11.6 and Jc = 4.2 Hz, 1H), 3.99 (ddd, Ja= 13.2, Jb = 5.6 and Jc = 2.2 Hz, 1H), 
5.47 (s, 1H), 6.13 (dd, Ja = 3.2 and Jb = 1.2 Hz, 1H), 6.36 (t, J = 3.2 Hz, 1H), 6.87 (td, Ja = 
7.6 and Jb = 1.5 Hz, 1H), 6.96−6.99 (m, 2H), 7.05−7.09 (m, 1H), 7.18 (dd, Ja = 2.9 and Jb = 
1.5 Hz, 1H), 7.26−7.29 (m, 1H), 7.32 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H), 7.42 (d, J = 1 Hz, 
1H); 
   
13C NMR (100 MHz, CDCl3) δ ppm = 25.9, 44.1, 56.0, 106.2, 110.2, 114.5, 115.1, 115.2, 
119.5, 119.8, 125.0, 127.0, 127.5, 130.1, 130.2, 130.8, 133.0, 136.7, 137.1; 
  
 HR-MS (ESI+) m/z calculated for C19H16BrN2+ = [M+H+]: 351.0491; found: 351.0477. 
 7, 11b-Dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (36g):  
Physical State   :White solid  
 Yield   :56 mg, 87%  
 Mp    :88−90 oC;  
   
 IR (MIR-ATR, 4000−600 cm-1) νmax = 3067, 2922, 2854, 1720, 1655, 
1614, 1489, 1387, 1295, 1238, 1119, 1031, 749, 697, 649; 
   
1H NMR (400 MHz, CDCl3) δ ppm = 2.94 (dt, Ja = 16.6 and  Jb = 4.4 Hz, 1H), 3.19−3.27 
(m, 1H), 3.53−3.61 (m, 1H), 3.92−3.98 (m, 1H), 6.88 (s, 1H), 7.08 (td, J = 7.6 Hz, 1H), 
7.14−7.17 (t, J = 7.6 Hz, 2H), 7.20−7.22 (m, 1H), 7.28−7.35 (m, 2H ), 7.47 (ddd, Ja = 8.4, Jb 
= 7.2 and Jc = 1.5 Hz, 1H), 8.03 (dd, Ja = 7.6 and Jb = 1.7 Hz, 1H ); 
  
 13C NMR (100 MHz, CDCl3) δ ppm = 25.8, 44.8, 72.0, 111.5, 116.2, 121.9, 126.3, 126.8, 
127.7, 129.3, 129.4, 129.8, 133.4, 134.5, 143.7, 148.8; 
   
 HR-MS (ESI+) m/z calculated for C16H14N5+ = [M+H+]: 276.1244; found: 276.1239. 
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 10-Methyl-7,11b-dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (36h):  
 Physical State   :White solid  
 Yield   :43 mg 68% 
 Mp    :170-172 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 2920, 1618, 1494, 
1303, 1214, 1144, 1064, 747, 612;  
 1H NMR (400 MHz, CDCl3) δ ppm = 2.28 (s, 3H), 2.89 (dt, Ja = 16.9 and Jb = 4 Hz, 1H), 
3.22(ddd, Ja = 16.5, Jb = 10.6 and Jc = 5.6 Hz, 1H), 3.54−3.61 (m, 1H), 3.95−4.01 (m, 1H), 
6.89 (s, 1H), 7.04−7.15 (m, 5H), 7.45−7.49 (m, 1H), 8.04 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
 13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 25.3, 44.9, 72.1, 111.4, 115.9, 121.7, 126.4, 
127.9, 129.2, 129.8, 130.3, 131.2, 133.4, 136.6, 143.6, 148.8; 
HR-MS (ESI+) m/z calculated for C17H16N5+ = [M+H+]: 290.1400; found: 290.1395. 
  
10-Bromo-7,11b-dihydro-6H-isoquinolino[2,1-a]tetrazolo[1,5-c]quinazoline (36i):  
Physical State   :white solid  
Yield   :46 mg, 75%  
Mp   :192−195 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 1618, 1580, 1488, 
1304, 1220, 1139, 816, 739; 
 1H NMR (400 MHz, CDCl3) δ ppm = 2.91 (dt, Ja = 17.1 and Jb = 3.9 Hz, 1H), 3.21 (ddd, Ja 
= 16.6, Jb = 10.5 and Jc = 5.6 Hz, 1H), 3.59 (ddd, Ja = 14.4, Jb = 10 and Jc = 4.9 Hz, 1H), 
3.99−4.05 (m, 1H), 6.91 (s, 1H), 7.05 (d, J = 8.3, 1H), 7.09−7.16 (m, 2H), 7.41−7.52 (m, 
3H), 8.06 (dd, Ja = 7.6 and Jb = 1.2 Hz, 1H); 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 25.1, 44.6, 71.4, 111.3, 116.0, 120.3, 122.1, 126.5, 
130.4, 131.0, 132.1, 132.6, 133.3, 133.6, 143.1, 148.7; 
   
 HR-MS (ESI+) m/z calculated for C16H13BrN5+ = [M+H+]: 354.0349; found: 354.0343. 
   
 6,17a-Dihydro-5H-benzo[4,5]imidazo[1,2-c]isoquinolino[2,1-a]quinazoline (36j):  
 Physical State   :White solid  
 Yield   :49 mg, 65%);  
 Mp.    :188−190 oC;  
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 IR (MIR-ATR, 4000−600 cm-1): νmax = 3054, 2921, 2851, 1613, 1479, 1449, 1226, 736, 642, 
546; 
  1H NMR (400 MHz, CDCl3) δ ppm = 2.86 (d, J = 17.1 Hz, 1H), 3.45−3.62 (m, 1H), 
3.76−3.81 (m, 1H), 4.32−4.45 (m, 1H), 7.16−6.74 (m, 7H), 7.47−7.25 (m, 4H), 7.88−7.86 
(m, 1H), 8.14 (d, J = 7.3 Hz, 1H); 
 13C NMR (100 MHz, CDCl3) δ ppm = 23.8, 44.9, 69.5, 109.3, 119.7, 123.0, 123.2, 125.6, 
126.2, 126.6, 128.7, 129.5, 131.9, 134.3, 134.2, 134.5, 135.45, 143.8; 
   
 HR-MS (ESI+) m/z calculated for C22H18N3+ = [M+H+]: 324.1495; found: 324.1494. 
   
 2-Methyl-6,17a-dihydro-5H-benzo[4,5]imidazo[1,2-c]isoquinolino[2,1-a]quinazoline 
(36k):  
 Physical State   :White solid  
Yield   :36 mg, 48% 
Mp.    :178−180 oC; 
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3049, 2920, 2851, 1613, 
1479, 1267, 1218, 736, 699, 641, 543; 
   
1H NMR (400 MHz, CDCl3) δ ppm = 2.04 (s, 3H), 2.83 (d, J = 14.7 Hz, 1H), 3.44−3.46 (m, 
1H), 3.78−3.82 (m, 1H), 4.27−4.31 (m, 1H), 6.51−6.54 (m, 1H), 6.84−7.05 (m, 5H), 
7.32−7.42 (m, 4H), 7.88 (d, J = 7.3 Hz, 1H), 8.14 (d, J = 7.3 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 23.5, 44.8, 69.3, 108.0, 109.1, 113.1, 119.5, 
122.8, 123.0, 126.1, 129.3, 129.4, 131.8, 134.5, 136.3, 143.7; 
HR-MS (ESI+) m/z calculated for C23H20N3+ = [M+H+]: 338.1652; found: 338.1650. 
  
5-(Phenylamino)-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (36l):  
Physical State   :White solid  
Yield   :50 mg, 62%  
Mp    :196−198 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3260, 3032, 2922, 2853, 
1655, 1599, 1472, 1267, 741, 697; 
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1H NMR (400 MHz, CDCl3) δ ppm = 2.75 (dd, Ja = 16.9 and Jb = 4.6, 1H), 3.26−3.35 (m, 
1H), 3.65 (ddd, Ja = 14.4, Jb = 12 and Jc = 5.4 Hz, 1H), 4.25 (dd, Ja = 14.4 and Jb = 5.1 Hz, 
1H), 5.98 (s, 1H), 6.84−6.87 (m, 1H), 6.92 (t, J = 7.3 Hz, 1H), 7.01−7.04 (m, 4H), 
7.09−7.15 (m, 2H), 7.22−7.26 (m, 2H), 7.31 (s, 1H), 7.38−7.42 (m, 1H), 7.53 (d, J = 7.3 Hz, 
1H), 7.9 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 24.4, 44.8, 75.1, 113.6, 114.2, 117.2, 119.5, 121.8, 
126.2, 126.4, 128.2, 129.0, 129.3, 129.4, 134.0, 134.2, 135.3, 146.7, 147.5, 163.1; 
  
HR-MS (ESI+) m/z calculated for C22H20N3O+ = [M+H+]: 342.1601; found: 342.1595. 
8-Chloro-5-(phenylamino)-12, 13-dihydro-4bH-isoquinolino[2, 1-a]quinazolin-6(5H)-one 
(36m):  
Physical State   :White solid  
Yield   :48 mg, 55% 
Mp    :125−127 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3263, 2916, 2754, 1657, 1488, 1248, 1099, 900, 739, 
691, 643, 591; 
1H NMR (400 MHz, CDCl3) δ ppm = 2.74 (dd, Ja = 16.9 and Jb = 4.6 Hz, 1H), 2.72−2.77 
(m, 1H), 3.22−3.31 (m, 1H), 3.61−3.68 (m, 1H), 4.17−4.22 (m, 1H), 5.96 (s, 1H), 6.92−6.93 
(m, 2H), 6.99−7.02 (m, 2H), 7.11−7.22 (m, 2H), 7.23−7.25 (m, 2H), 7.31−7.34 (m, 1H), 
7.44 (br. s, 1H), 7.53 (d, J = 7.3 Hz, 1H), 7.86−7.87 (m, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 24.3, 45.0, 75.2, 114.1, 115.1, 118.4, 121.8, 124.8, 
126.3, 126.4, 128.4, 128.9, 129.0, 129.4, 133.8, 133.9, 135.0, 146.1, 146.5, 162.1; 
HR-MS (ESI+) m/z calculated for C22H19ClN3O+ = [M+H+]: 376.1211; found: 376.1204. 
  
5-Phenyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (36n):  
Physical State   :White solid  
Yield   :54 mg, 70% 
Mp    :92−94 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3065, 1667, 1598, 1462, 
1378, 1326, 1275, 755, 695, 662;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.83 (dd, Ja = 17.1 and Jb = 4.4, 1H), 3.26−3.29 (m, 
1H), 3.72 (ddd, Ja = 14.7, Jb = 11.2 and  Jc = 5.9 Hz, 1H), 4.20−4.26 (m, 1H), 6.16 (s, 1H), 
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6.85−6.89 (m, 1H), 6.98 (d, J = 8.3 Hz, 1H), 7.03−7.08 (m, 2H), 7.13−7.16 (m, 1H), 
7.19−7.23 (m, 1H), 7.32−7.40 (m, 4H), 7.48−7.50 (m, 2H), 7.99 (dd, Ja = 7.8 and Jb = 2 Hz, 
1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 24.6, 45.1, 75.3, 114.1, 119.2, 119.7, 125.1, 125.9, 
126.2, 127.2, 128.2, 128.9, 129.1, 129.9, 133.8, 134.4, 135.6, 141.7, 147.4, 162.8; 
  
HR-MS (ESI+) m/z calculated for C22H19N2O+ = [M+H+]: 327.1492; found: 327.1486. 
5-Benzyl-12, 13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)- one (36o):  
Physical State   :White solid  
Yield   :52 mg, 65%  
Mp    :158−160 oC; 
  
IR (MIR-ATR, 4000−600 cm-1): νmax  = 3030, 2917, 1648, 1601, 
1475, 1261, 744, 697; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 2.29 (dd, Ja = 16.9 and Jb = 3.7 Hz, 1H), 3.13−3.04 
(m, 1H), 3.48 (ddd, Ja = 14.1, Jb = 11.1 and Jc = 5.6 Hz, 1H), 3.98 (dd, Ja = 13.7 and Jb = 5.4 
Hz, 1H), 4.36 (d, J = 15.2 Hz, 1H), 5.72−5.85 (m, 2H), 6.82−6.88 (m, 2H), 6.99−7.01 (m, 
1H), 7.13−7.19 (m, 2H), 7.22−7.35 (m, 7H), 7.95 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 24.5, 44.6, 49.7, 71.7, 113.7, 118.5, 119.4, 119.8, 
125.9,  126.2, 127.5, 127.7, 128.3, 128.7, 129.3, 129.5, 133.4, 134.8, 137.3, 147.5, 163.5; 
  
HR-MS (ESI+) m/z calculated for C23H21N2O+ = [M+H+]: 341.1648; found: 341.1644. 
5-Benzyl-8-chloro-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (36p):  
Physical State   :White solid     
Yield   :48 mg, 55%  
Mp    :210−212 oC;  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3062, 2920, 1652, 1476, 1259, 
737, 699, 639; 
1H NMR (400 MHz, CDCl3) δ ppm = 2.71 (dd, Ja = 17.1 and Jb = 3.9 
Hz, 1H), 3.03−3.11 (m, 1H), 3.5 ( ddd, Ja = 14.2, Jb = 11 and Jc = 5.6 Hz, 1H), 3.95 (dd, Ja = 
13.7 and Jb = 5.4 Hz, 1H), 4.35 (d, J = 15.2 Hz, 1H), 5.64−5.68 (m, 2H), 6.82 (d, J = 8.8 
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Hz, 1H), 7.02 (d, J = 6.8 Hz, 1H), 7.15−7.21 (m, 2H), 7.23−7.32 (m, 7H), 7.91 (d, J = 2.4 
Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 24.4, 44.7, 49.8, 71.7, 104.9, 109.8, 115.2, 124.7, 
125.8, 126.4, 127.6, 127.7, 128.5, 128.7, 129.1, 129.3, 133.3, 134.5, 136.9, 146.0, 162.4; 
  
HR-MS (ESI+) m/z calculated for C23H20ClN2O+ = [M+H+]: 375.1259; found: 375.1250. 
5-Benzyl-3-methyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one (36q):  
Physical State   :White solid  
Yield   :47 mg, 60% 
Mp    :158−160 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3032, 2917, 1647, 1603, 1476, 
1384, 1264, 1169, 818, 738, 698; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 2.27 (s, 3H), 2.66 (dd, Ja = 16.6 and Jb = 4.4 Hz, 1H), 
3.08 (d, J = 6.4 Hz, 1H), 3.49 (ddd, Ja = 14.2, Jb = 11.2 and Jc = 5.9 Hz, 1H), 4.01 (dd, Ja = 
13.9 and Jb = 5.6 Hz, 1H), 4.34 (d, J = 15.7 Hz, 1H), 5.64 (s, 1H), 5.74 (s, 1H), 6.83−6.92 
(m, 3H), 6.99− 7.02 (m, 2H), 7.27−7.34 (m, 6H), 7.97 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 21.2, 24.1, 44.7, 49.9, 71.8, 113.6, 118.4, 119.3, 
126.4, 127.5, 127.7, 128.7, 129.0, 129.1, 129.5, 131.6, 133.4, 135.8, 137.3, 147.5, 163.5;  
HR-MS (ESI+) m/z calculated for C24H23N2O+ = [M+H+]: 355.1805; found: 355.1799. 
5-Benzyl-8-chloro-3-methyl-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-
6(5H)-one (36r): 
Physical State    :White solid  
Yield    :41 mg, 48%. 
Mp     :152−155 oC; 48% yield;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 2912, 2753, 1649, 1454, 
1255, 1103, 889, 809, 732, 698, 640, 589, 539;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.27 (s, 3H), 2.66 (dd, J = 16.9 and 4.6, 1H), 
3.01−3.09 (m, 1H), 3.48 (ddd, Ja = 14.2, Jb = 11.2 and Jc = 5.9 Hz, 1H), 3.94 (dd, Ja = 13.7 
and Jb = 5.9 Hz, 1H), 4.32 (d, J = 15.2 Hz, 1H), 5.61 (s, 1H), 5.72 (d, J = 12.2 Hz, 1H), 6.8 
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(d, J = 8.8 Hz, 1H), 6.9−6.92 (m, 1H), 6.99−7.01 (m, 2H), 7.24−7.33 (m, 6H), 7.91 (d, J = 
2.4 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm =  21.2, 24.0, 44.8, 50.0, 71.8, 115.1, 119.6, 124.6, 
126.3, 127.6, 127.7, 128.7, 129.1, 129.2, 129.3, 131.3, 133.2, 136.0, 137.0, 146.0, 162.4; 
  
HR-MS (ESI+) m/z calculated for C24H22ClN2O+ = [M+H+]: 389.1415; found: 389.1408. 
5-Benzyl-3-bromo-12,13-dihydro-4bH-isoquinolino[2,1-a]quinazolin-6(5H)-one 
(36s):  
Physical State   :White solid 
Yield   :43 mg, 62% 
Mp   :128−130 oC 
  
IR (MIR-ATR, 4000−600 cm-1) νmax = 3340, 3057, 2919, 1647, 1603, 1477, 1260, 1167, 
816, 734, 697, 629, 546;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.64 (dd, Ja = 17.1 and Jb = 4.9 Hz, 1H), 3.07−3.11 
(m, 1H), 3.5 (ddd, Ja = 14.4, Jb = 11.5 and Jc = 5.9 Hz, 1H), 4.07 (dd, Ja = 14.2 and Jb = 5.9 
Hz, 1H), 4.3 (d, J = 15.7 Hz, 1H), 5.6 (s, 1H), 5.81 (d, J = 15.2 Hz, 1H), 6.86−6.89 (m, 3H), 
7.26−7.36 (m, 8H), 7.96 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 23.6, 44.3, 50.1, 71.4, 113.4, 118.2, 119.6, 119.9, 
127.6, 127.7, 128.6, 128.8, 129.62, 130.9, 131.4, 133.5, 133.6, 136.9, 146.9, 163.1; 
  
HR-MS (ESI+) m/z calculated for C23H20BrN2O+ = [M+H+]: 419.0754; found: 419.0746. 
4b,5,12,13-Tetrahydrobenzo[5,6]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (36t):  
Physical State   :White solid  
Yield   :47 mg, 70% 
Mp    :218−220 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax =  3231, 2922, 2853, 
1597, 1481, 1449, 1318, 1274, 1158, 748, 662, 610, 556;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.98−3.14 (m, 2H), 3.46 (ddd, Ja = 12.3, Jb = 8.2 and 
Jc = 4.4 Hz, 1H), 3.86 (dt, Ja = 12.5 and  Jb = 5.3 Hz, 1H), 4.77 (d, J = 12.7 Hz, 1H), 5.98 (d, 
J = 13.2 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.3 Hz, 1H), 7.20−7.23 (m, 1H), 
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7.30−7.33 (m, 2H), 7.45 (ddd, Ja = 8.6, Jb = 7.1 and Jc = 1.5 Hz, 1H), 7.6 (dd, Ja = 5.4 and 
Jb = 3.9 Hz, 1H), 7.78 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 43.8, 68.5, 116.1, 119.4, 125.3, 125.4, 127.1, 
127.7, 128.3, 128.7, 131.7, 133.5, 135.0, 144.5; 
  
HR-MS (ESI+) m/z calculated for C15H15N2O2S+ = [M+H+]: 287.0849; found: 287.0845. 
8-Chloro-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-
dioxide (36u): 
Physical State    :White solid  
Yield    :69 mg, 90% 
Mp     :198−200 oC; 
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3222, 3065, 2925, 2849, 1597, 1478, 1322, 1160, 
734, 666, 621, 554;  
1H NMR (400 MHz, CDCl3) δ ppm = 3.0−3.1 (m, 2H), 3.46 (ddd, Ja = 12.2, Jb = 8.1 and Jc 
= 4.6 Hz, 1H), 3.78−3.84 (m, 1H), 4.93 (d, J = 12.7 Hz, 1H), 5.95 (d, J = 12.7 Hz, 1H), 7.0 
(d, J = 8.8 Hz, 1H), 7.21−7.23 (m, 1H), 7.31−7.38 (m, 3H), 7.57 (dd, Ja = 5.1 and Jb = 3.7 
Hz, 1H), 7.7 (d, J = 2.4 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ ppm = 28.9, 44.0, 68.3, 117.8, 124.3, 124.7, 125.9 , 127.2, 
127.7, 128.3, 128.8, 131.2, 133.6, 134.8, 143.1; 
  
HR-MS (ESI+) m/z calculated for C15H14ClN2O2S+ = [M+H+]: 321.0459; found: 321.0454. 
  
8-Bromo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 
6,6-dioxide (36v):  
Physical State   : White solid 
Yield   : 70 mg, 82%) 
Mp    : 200−202 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3411, 3027, 2837, 2720, 2253, 2128, 1644, 1593, 
1476, 1322, 1164, 1005, 820, 758, 617, 561; 
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1H NMR (400 MHz, CDCl3) δ ppm = 2.98−3.10 (m, 2H), 3.43−3.47 (td, Ja = 8.2 and Jb = 
4.2 Hz, 1H), 3.78−3.83 (m, 1H), 4.95 (d, J = 12.7 Hz, 1H), 5.93 (d, J = 12.7 Hz, 1H), 6.93 
(d, J = 9.3 Hz, 1H), 7.21−7.24 (m, 1H), 7.30−7.35 (m, 2H), 7.47−7.5 (m, 1H), 7.54−7.57 
(m, 1H), 7.82 (d, J = 2.4 Hz, 1H);  
13C NMR (100 MHz, CDCl3) δ ppm = 28.9, 43.9, 68.4, 111.2, 117.8, 126.3, 127.3, 127.6, 
127.8, 128.3, 128.9, 131.2, 134.8, 136.4, 143.4; 
  
HR-MS (ESI+) m/z calculated for C15H14BrN2O2S+ = [M+H+]: 364.9954; found: 364.9948. 
8-Iodo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 6,6-
dioxide (36w):  
Physical State   :  White solid                                                 
Yield   :  76 mg, 79%b 
Mp    :  210−212 oC; 
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3419, 1649, 1402, 1175, 1006, 821, 759, 618, 568; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 2.55−2.61 (m, 1H), 2.96−3.13 (m, 1H), 3.47 (ddd, Ja 
= 12.1, Jb = 7.5 and Jc = 4.4 Hz, 1H), 3.77−3.83 (m, 1H), 5.9 (d, J = 12.2 Hz, 1H), 6.84 (d, J 
= 8.8 Hz, 1H), 7.20−2.22 (m, 1H), 7.29−7.38 (m, 2H), 7.55−7.57 (m, 1H), 7.64 (dd, Ja = 8.8 
and Jb = 2 Hz, 1H), 7.98 (d, J = 2 Hz, 1H);  
13C NMR (100 MHz, CDCl3) δ ppm = 28.9, 43.8, 68.3, 79.9, 117.9, 126.7, 127.3, 127.6, 
128.3, 128.9, 131.3, 133.4, 134.8, 142.0, 143.9; 
  
HR-MS (ESI+) m/z calculated for C15H14IN2O2S+ = [M+H+]: 412.9815; found: 412.9809. 
3-Methyl-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 
6,6-dioxide (36x):  
Physical State   :White solid                          
Yield   :41 mg, 62% 
Mp    :228−230 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3205, 2918, 2851, 1715, 1594, 1450, 1319, 1156, 
741, 664, 559;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.36 (s, 3H), 2.96−3.04 (m, 2H), 3.42 (ddd, Ja = 12.3, 
Jb = 8.2 and Jc = 4.2 Hz, 1H), 3.83 (dt, Ja = 12.1 and Jb = 5.2 Hz, 1H), 4.78 (d, J = 12.7 Hz, 
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1H), 5.92 (d, J = 13.2 Hz, 1H), 6.94−6.96 (m, 1H), 7.05−7.14 (m, 3H), 7.40−7.46 (m, 2H), 
7.76 (dd, Ja = 7.8 and Jb = 1.5 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 28.6, 43.9, 68.6, 116.1, 119.4, 125.3, 125.4, 
128.2, 129.6, 131.4, 131.8, 133.5, 136.9, 144.6; 
  
HR-MS (ESI+) m/z calculated for C16H17N2O2S+ = [M+H+]: 301.1005; found: 301.1001. 
8-Iodo-3-methyl-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4 
a]isoquinoline 6,6-dioxide (36y):  
Physical State   :White solid                          
Yield   :64 mg, 68% 
Mp   :218−220 oC; 
  
IR (MIR-ATR, 4000−600 cm-1): νmax  = 3217, 2921, 2854, 1469, 1322, 1273, 1160, 929, 
798, 730, 665; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 2.36 (s, 3H), 2.92− 3.05 (m, 2H), 3.41 (ddd, Ja = 12.3, 
Jb = 8.4 and Jc = 4.2 Hz, 1H), 3.78−3.83 (m, 1H), 4.88 (d, J = 12.7 Hz, 1H), 5.9 (d, J = 12.7 
Hz, 1H), 6.81 (d, J = 9.3 Hz, 1H), 7.09−7.14 (m, 2H), 7.38 (s, 1H), 7.66 (dd, Ja = 8.8 and Jb 
= 2 Hz, 1H), 7.99 (d, J = 2 Hz, 1H); 
  
13C NMR (100 MHz, CDCl3) δ ppm = 21.1, 28.5, 43.9, 68.4, 79.9, 117.9, 126.7, 128.0, 
128.2, 129.7, 131.0, 131.7, 133.5, 137.1, 142.0, 143.9; 
HR-MS (ESI+) m/z calculated for C16H16IN2O2S+ = [M+H+]: 426.9972; found: 426.9962. 
 3-Bromo-4b,5,12,13-tetrahydrobenzo[5,6][1,2,4]thiadiazino[3,4-a]isoquinoline 
6,6-dioxide (36z):  
 Physical State    :White solid  
 Yield    :54 mg, 65% 
 Mp     :228−230 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3213, 2924, 2852, 
1706, 1598, 1478, 1319, 1161, 738, 548;  
 1H NMR (400 MHz, CDCl3) δ ppm = 2.90−2.96 (m, 2H), 3.36 (ddd, Ja = 12.5, Jb = 7.8 and 
Jc = 4.6 Hz, 1H), 3.74−3.79 (m, 1H), 4.83 (d, J = 12.7 Hz, 1H), 5.81 (d, J = 13.2 Hz, 1H), 
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6.87−6.92 (m, 1H), 7.01 (dd, Ja = 10.3 and Jb = 8.8 Hz, 2H), 7.34−7.40 (m, 2H), 7.64−7.67 
(m, 2H);  
 13C NMR (100 MHz, CDCl3) δ ppm = 28.6, 43.7, 67.9, 116.4, 119.8, 120.7, 125.4, 125.5, 
130.0, 130.7, 131.9, 133.6, 133.9, 144.2; 
   
 HR-MS (ESI+) m/z calculated for C15H14BrN2O2S+ = [M+H+]: 364.9954; found: 364.9951. 
 4b,6,12,13-Tetrahydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinoline (36aa):  
 Physical State    :White solid  
 Yield    :33 mg, 60% 
 Mp     :115−117 oC;  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3035, 2933, 2897, 2838, 
1602, 1491, 1455, 1389, 1287, 1228, 1193, 1154, 1056, 1029, 946, 749, 664; 
   
 1H NMR (400 MHz, CDCl3) δ ppm = 2.91 (dt, Ja = 15.9 and Jb = 3.5 Hz, 1H), 3.14 (ddd, Ja 
= 16, Jb = 10.6 and Jc = 5.1 Hz, 1H), 3.44−3.58 (m, 2H), 4.96 (d, J = 15.2 Hz, 1H), 5.22 (d, 
J = 14.7 Hz, 1H), 5.41 (s, 1H), 6.95−7.02 (m, 2H), 7.11 (d, J = 7.8 Hz, 1H), 7.17−7.28 (m, 
4H), 7.45 (dd, Ja= 5.4 and Jb = 3.9 Hz, 1H). 
   
13C NMR (100 MHz, CDCl3) δ ppm = 29.8, 46.2, 68.3, 84.4, 121.2, 121.7, 1245.0, 126.3, 
126.4, 127.3, 128.3, 128.7, 133.4, 135.3, 146.0;  
 HR-MS (ESI+) m/z calculated for C16H14N+ = [[M+H+]-H2O]: 220.1120; found: 220.1113. 
12,13-Dihydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinolin-6(4bH)-one (36ab):  
 Physical State   :White solid  
 Yield   :43 mg, 72% 
 Mp    :115−117 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 1720, 1607, 1484, 1467, 1399, 1331, 1292, 1229, 
752;  
 1H NMR (400 MHz, CDCl3) δ ppm =  3.1 (t, Ja = 5.9, Jb = 5.9 Hz, 2H), 3.46−3.52 (m, 1H), 
3.71− 3.76 (m, 1H), 6.14 (s, 1H), 7.11−7.13 (m, 2H), 7.26−7.24 (m, 1H), 7.33−7.36 (m, 
2H), 7.55−7.59 (m, 2H), 8.11 (dd, J = 7.8 Hz, 1.5, 1H); 
   
13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 43.6, 85.7, 117.0, 117.2, 122.0, 127.0, 128.4, 
128.6, 129.3, 130.0, 131.0, 134.7, 135.1, 150.0, 165.1; 
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 HR-MS (ESI+) m/z calculated for C16H14NO2+ = [M+H+]: 252.1019; found: 252.1008. 
 6-Phenyl-4b,6,12,13-tetrahydrobenzo[4,5][1,3]oxazino[2,3-a]isoquinoline (36ac):  
Physical State   :Brown solid                           
 Yield   :35 mg, 52% 
Mp    :60−62 oC ;  
   
IR (MIR-ATR, 4000-600 cm-1): νmax  = 3029, 2925, 2834, 1659, 1601, 1487.44, 1455, 1391, 
1221, 1146, 939, 747, 699, 644;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.85−2.99 (m, 2H), 3.18−3.23 (m, 2H), 3.55−3.60 (m, 
2H), 3.71−3.72 (m, 1H), 3.98 (t, J = 5.9 Hz, 1H), 5.36 (s, 1H), 5.68 (s, 1H), 6.04 (s, 1H), 
6.21 (s, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.85−6.88 (m, 1H), 6.97−7.05 (m, 3H), 7.15−7.16 (m, 
4H), 7.21−7.25 (m, 4H), 7.29−7.32 (m, 2H), 7.33−7.43 (m, 4H), 7.43−7.51 (m, 7H); 
  
13C, HMBC, HSQC NMR (100 MHz, CDCl3) δ ppm = 29.7 (t, -CH2-), 29.9 (t, -CH2-), 46.1 
(t, -CH2-), 47.0 (t, -CH2-), 77.07 (d, -CH-), 78.2 (d, -CH-), 81.5 (d, -CH-), 84.4 (d, -CH-), 
120.9 (d, Ar-CH), 121.0 (d, Ar-CH), 121.7 (s, Ar-C), 121.8 (d, Ar-CH), 122.0 (d, Ar-CH), 
125.8 (s, Ar-C), 126.3 (d, Ar-CH), 126.4 (d, Ar-CH), 127.3 (d, Ar-CH), 127.6 (d, Ar-CH), 
127.9 (d, Ar-CH), 128.0 (d, 2C, Ar-CH), 128.0 (d, 2C, Ar-CH), 128.1 (d, Ar-CH), 128.2 (d, 
2C, Ar-CH), 128.3 (s, Ar-C), 128.4 (d, 2C, Ar-CH), 128.5 (d, Ar-CH), 128.5 (d, 2C, Ar-
CH), 128.8 (d, 2C, Ar-CH), 129.1 (d, Ar-CH), 129.4 (d, 2C, Ar-CH), 130.3 (s, Ar-C), 133.4 
(s, Ar-C), 135.1 (s, Ar-C), 135.4 (s, Ar-C), 141.8 (s, Ar-C), 142.4 (s, Ar-C), 146.4 (s, Ar-C). 
12,12',13,13'-Tetrahydro-[5,5'-biisoquinolino[2,1-a]quinazoline]-6,6'(4bH,4'bH)-
dione (36ae): 
Physical State   :White solid                              
Yield   :45 mg, 38% 
Mp    :230−232 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 2903, 1722, 1606, 1466, 1398, 1294, 1241, 1160, 
1119, 1032, 951, 750, 697, 639;  
1H NMR (400 MHz, CDCl3) δ ppm = 2.90−2.93 (m, 2H), 3.45−3.62 (m, 2H), 6.48 (s, 1H), 
7.32−7.49 (m, 1H), 7.50−7.53 (m, 3H), 7.81−7.91 (m, 3H), 8.33−8.35 (m, 1H);  
13C NMR (100 MHz, CDCl3) δ ppm = 29.0, 45.0, 72.7, 118.7, 120.3, 121.7, 125.9, 127.7, 
128.1, 128.9, 129.6, 130.6, 133.9, 136.4, 150.0, 166.6;  
HR-MS (ESI+) m/z calculated for C32H27N4O2+ = [M+H+]: 499.2129; found: 499.2127.  
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X-ray crystal structure data for 5-Benzyl-8-chloro-12,13-dihydro-4bH-
isoquinolino[2,1-a]quinazolin-6(5H)-one (3p) CCDC 1478499 
 
 
X-ray crystal structure of product 3p. Thermal ellipsoids are drawn at 50% 
probability level.  
 
Operator K. Ravikumar  
Difractometer Oxford Super Nova                   
Empirical formula C23H20N2OCl 
Formula weight 374.87 
Temperature/K 300 
Crystal system monoclinic 
Space group P21/n 
a/Å 13.3763(7) 
b/Å 9.9725(5) 
c/Å 14.0504(7) 
α/° 90 
β/° 96.255(4) 
γ/° 90 
Volume/Å3 1863.10(16) 
Z 4 
ρcalcg/cm3 1.3364 
μ/mm-1 1.926 
F(000) 787.6 
Crystal size/mm3 0.08 × 0.07 × 0.04 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 8.66 to 141.54 
Index ranges -16 ≤ h ≤ 16, -12 ≤ k ≤ 12, -9 ≤ l ≤ 16 
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Reflections collected 7614 
Independent reflections 3510 [Rint = 0.0287, Rsigma = 0.0343] 
Data/restraints/parameters 3510/0/250 
Goodness-of-fit on F2 1.082 
Final R indexes [I>=2σ (I)] R1 = 0.0457, wR2 = 0.1189 
Final R indexes [all data] R1 = 0.0636, wR2 = 0.1395 
Largest diff. peak/hole / e Å-3 0.20/-0.22 
 
X-ray crystal structure data for 4b,5,12,13 
Tetrahydrobenzo[5,6]thiadiazino[3,4-a]isoquinoline 6,6-dioxide (3t) CCDC 
1478644  
 
X-ray crystal structure of product 3t. Thermal ellipsoids are drawn at 50% 
probability level.  
 
Operator Jayeeta Battacharyagee  
Difractometer Oxford Super Nova                   
Empirical formula C15H14NO2S 
Formula weight 286.36 
Temperature/K 293 
Crystal system orthorhombic 
Space group P212121 
a/Å 7.9410(4) 
b/Å 11.9290(5) 
c/Å 13.9233(7) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 1318.94(11) 
Z 4 
ρcalcg/cm3 1.4420 
μ/mm-1 2.209 
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F(000) 603.1 
Crystal size/mm3 0.06 × 0.05 × 0.04 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 9.76 to 141.58 
Index ranges -8 ≤ h ≤ 9, -10 ≤ k ≤ 14, -12 ≤ l ≤ 16 
Reflections collected 3421 
Independent reflections 2073 [Rint = 0.0204, Rsigma = 0.0317] 
Data/restraints/parameters 2073/0/183 
Goodness-of-fit on F2 1.061 
Final R indexes [I>=2σ (I)] R1 = 0.0609, wR2 = 0.1603 
Final R indexes [all data] R1 = 0.0627, wR2 = 0.1628 
Largest diff. peak/hole / e Å-3 0.56/-0.40 
Flack parameter 0.47(9) 
 
X-ray crystal structure data for 12,12',13,13'-Tetrahydro-[5,5'-
biisoquinolino[2,1-a]quinazoline]-6,6'(4bH,4'bH)-dione (3ae) CCDC 1478494 
 
X-ray crystal structure of product 3ae. Thermal ellipsoids are drawn at 50% 
probability level. 
Operator Jayeeta Battacharyagee  
Difractometer Oxford Super Nova                   
Empirical formula C4.57H3.71N0.57O0.29 
Formula weight 284.91 
Temperature/K 293 
Crystal system orthorhombic 
Space group P212121 
a/Å 10.3261(8) 
b/Å 15.0211(8) 
c/Å 16.2026(9) 
α/° 90 
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β/° 90 
γ/° 90 
Volume/Å3 2513.2(3) 
Z 7 
ρcalcg/cm3 1.3176 
μ/mm-1 0.668 
F(000) 1051.2 
Crystal size/mm3 0.4 × 0.2 × 0.2 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 8.02 to 142.46 
Index ranges -12 ≤ h ≤ 6, -18 ≤ k ≤ 16, -19 ≤ l ≤ 15 
Reflections collected 6242 
Independent reflections 4258 [Rint = 0.0319, Rsigma = 0.0831] 
Data/restraints/parameters 4258/0/342 
Goodness-of-fit on F2 1.026 
Final R indexes [I>=2σ (I)] R1 = 0.0668, wR2 = 0.1464 
Final R indexes [all data] R1 = 0.1106, wR2 = 0.1876 
Largest diff. peak/hole / e Å-3 0.25/-0.32 
Flack parameter 0.2(8) 
Mechanistic experimental study 
To probe the  
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Table 2. Optimization for increasing the diastereoselectivitya  
 
Entry Solvent Tempt (oC) Time (min) drc (cis:trans)d 
1 DCE rt 90 4:3 
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2 DCE reflux 30 4:3 
2 MeOH rt 90 4:3 
3 MeOH reflux 30 4:3 
4 1,4-dioxane rt 90 4:3 
 5 1,4-dioxane reflux 30 4:3 
6 CH3CN rt 90 4:3 
7 CH3CN reflux 30 4:3 
aReaction conditions: 1a (0.23 mmol), 2S7 (0.23 mmol) and 1 mL of solvent; b 
Isolated yields after column chromatography; cThe dr value was determined by 
NMR spectroscopy of the crude reaction mixture; d Mixture of cis:trans 
diastereoisomers in 4:3 ratio confirmed by NOESY spectroscopy.  
 
 
 
Copies of 1H and 13C NMR spectra of compounds 36a-36ac 
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 Figure 6.  1H NMR (400 MHz) spectrum of compound 36a in CDCl3. 
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Figure 7.  13C NMR (100 MHz) spectrum of compound 36a in CDCl3.  
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Figure 8.  1H NMR (400 MHz) spectrum of compound 36b in CDCl3. 
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 Figure 9.  13C NMR (100 MHz) spectrum of compound 36b in CDCl3.  
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Figure 10.  1H NMR (400 MHz) spectrum of compound 36c in CDCl3. 
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Figure 11.  13C NMR (100 MHz) spectrum of compound 36c in CDCl3.  
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Figure 12.  1H NMR (400 MHz) spectrum of compound 36d in CDCl3. 
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Figure 13.  13C NMR (100 MHz) spectrum of compound 36d in CDCl3.  
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Figure 14.  1H NMR (400 MHz) spectrum of compound 36e in CDCl3. 
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Figure 15.  13C NMR (100 MHz) spectrum of compound 36e in CDCl3.  
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Figure 16.  1H NMR (400 MHz) spectrum of compound 36f in CDCl3. 
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Figure 17.  13C NMR (100 MHz) spectrum of compound 36f in CDCl3.  
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 Figure 18.  1H NMR (400 MHz) spectrum of compound 36g in CDCl3. 
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 Figure 19.  13C NMR (100 MHz) spectrum of compound 36g in CDCl3 
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Figure 20.  1H NMR (400 MHz) spectrum of compound 36h in CDCl3. 
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 Figure 21.  13C NMR (100 MHz) spectrum of compound 36h in CDCl3 
56 
 
 
 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
1.000.980.961.000.900.871.890.492.700.89
8
.0
7
8
.0
5
8
.0
5
7
.5
0
7
.4
6
7
.4
3
7
.4
1
7
.2
7
7
.1
6
7
.1
4
7
.1
1
7
.0
6
7
.0
4
6
.9
1
4
.0
3
4
.0
2
4
.0
1
4
.0
0
3
.9
9
3
.6
1
3
.6
0
3
.5
9
3
.5
7
3
.2
1
2
.9
4
2
.9
3
2
.9
2
2
.8
8
0
.0
0
 
 Figure 22.  1H NMR (400 MHz) spectrum of compound 36i in CDCl3. 
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 Figure 23.  13C NMR (100 MHz) spectrum of compound 36i in CDCl3 
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Figure 24.  1H NMR (400 MHz) spectrum of compound 36j in CDCl3. 
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 Figure 25.  13C NMR (100 MHz) spectrum of compound 36j in CDCl3 
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Figure 26.  1H NMR (400 MHz) spectrum of compound 36k in CDCl3. 
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 Figure 27.  13C NMR (100 MHz) spectrum of compound 36k in CDCl3 
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    Figure 28.  1H NMR (400 MHz) spectrum of compound 36l in CDCl3. 
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      Figure 29.  13C NMR (100 MHz) spectrum of compound 36l in CDCl3 
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Figure 30.  1H NMR (400 MHz) spectrum of compound 36m in CDCl3. 
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 Figure 31.  13C NMR (100 MHz) spectrum of compound 36m in CDCl3 
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Figure 32.  1H NMR (400 MHz) spectrum of compound 36n in CDCl3. 
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 Figure 33.  13C NMR (100 MHz) spectrum of compound 36n in CDCl3 
 
 
 
62 
 
 
 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
1.000.980.980.980.971.821.830.951.906.760.89
7
.9
7
7
.9
6
7
.9
5
7
.3
5
7
.3
3
7
.3
1
7
.3
0
7
.2
8
7
.2
5
7
.2
4
7
.1
6
6
.8
8
6
.8
6
6
.8
4
5
.6
6
4
.3
8
4
.3
4
3
.9
9
3
.9
7
3
.5
0
3
.4
9
3
.4
8
3
.4
8
3
.4
7
3
.4
6
3
.4
4
3
.0
8
2
.7
1
2
.7
0
2
.6
7
2
.6
6
1
.2
6
0
.0
0
 Figure 34.  1H NMR (400 MHz) spectrum of compound 36o in CDCl3. 
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 Figure 35.  13C NMR (100 MHz) spectrum of compound 36o in CDCl3 
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 Figure 36.  1H NMR (400 MHz) spectrum of compound 3p in CDCl3. 
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 Figure 37.  13C NMR (100 MHz) spectrum of compound 36p in CDCl3 
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Figure 38.  1H NMR (400 MHz) spectrum of compound 3q in CDCl3. 
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 Figure 39.  13C NMR (100 MHz) spectrum of compound 36q in CDCl3 
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  Figure 40.  1H NMR (400 MHz) spectrum of compound 36r in CDCl3. 
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 Figure 41.  13C NMR (100 MHz) spectrum of compound 36r in CDCl3 
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 Figure 42.  1H NMR (400 MHz) spectrum of compound 36s in CDCl3. 
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 Figure 43.  13C NMR (100 MHz) spectrum of compound 36s in CDCl3 
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Figure 44.  1H NMR (400 MHz) spectrum of compound 36t in CDCl3. 
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 Figure 45.  13C NMR (100 MHz) spectrum of compound 3t in CDCl3 
 
 
 
 
68 
 
        
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
2.000.880.940.870.820.901.432.690.870.79
7
.7
0
7
.7
0
7
.3
8
7
.3
6
7
.3
4
7
.3
3
7
.3
2
7
.3
2
7
.2
6
7
.0
1
6
.9
9
5
.9
6
5
.9
3
4
.9
4
4
.9
1
3
.8
2
3
.8
1
3
.7
9
3
.4
7
3
.4
6
3
.1
0
3
.0
9
3
.0
8
3
.0
7
3
.0
5
3
.0
4
3
.0
2
1
.6
0
0
.0
0
 
 Figure 46.  1H NMR (400 MHz) spectrum of compound 36u in CDCl3. 
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 Figure 47.  13C NMR (100 MHz) spectrum of compound 36u in CDCl3 
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 Figure 48.  1H NMR (400 MHz) spectrum of compound 36v in CDCl3. 
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 Figure 49.  13C NMR (100 MHz) spectrum of compound 36v in CDCl3 
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      Figure 50.  1H NMR (400 MHz) spectrum of compound 36w in CDCl3. 
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 Figure 51.  13C NMR (100 MHz) spectrum of compound 36w in CDCl3 
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 Figure 52.  1H NMR (400 MHz) spectrum of compound 36x in CDCl3. 
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Figure 53.  13C NMR (100 MHz) spectrum of compound 36x in CDCl3 
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Figure 54.  1H NMR (400 MHz) spectrum of compound 36y in CDCl3. 
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 Figure 55.  13C NMR (100 MHz) spectrum of compound 36y in CDCl3 
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Figure 56.  1H NMR (400 MHz) spectrum of compound 36z in CDCl3. 
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 Figure 57.  13C NMR (100 MHz) spectrum of compound 36z in CDCl3.  
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 Figure 58.  1H NMR (400 MHz) spectrum of compound 36aa in CDCl3. 
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 Figure 59.  13C NMR (100 MHz) spectrum of compound 36aa in CDCl3.  
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 Figure 60.  1H NMR (400 MHz) spectrum of compound 36ab in CDCl3. 
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 Figure 61.  13C NMR (100 MHz) spectrum of compound 36ab in CDCl3 
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 Figure 62.  1H NMR (400 MHz) spectrum of compound 36ac in CDCl3. 
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 Figure 63.  13C NMR (100 MHz) spectrum of compound 36ac in CDCl3 
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Figure 68.  1H NMR (400 MHz) spectrum of compound 36ae in CDCl3. 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
6
6
.6
3
1
4
9
.9
7
1
3
6
.3
5
1
3
3
.8
9
1
3
0
.5
6
1
2
9
.6
1
1
2
8
.9
3
1
2
8
.1
2
1
2
5
.9
0
1
2
1
.7
1
1
2
0
.2
7
1
1
8
.7
0
7
7
.3
9
7
7
.0
7
7
6
.7
6
7
2
.6
6
4
4
.9
9
2
8
.9
8
 
 Figure 69.  13C NMR (100 MHz) spectrum of compound 36ae in CDCl3 
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Figure 64.  NOESY spectrum of compound 36ac in CDCl3 
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Figure 65.  COSY spectrum of compound 36ac in CDCl3 
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Figure 66.  HMBC spectrum of compound 36ac in CDCl3 
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Figure 67.  HSQC spectrum of compound 36ac in CDCl3 
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CHAPTER III 
 
Copper-Catalyzed Intramolecular α-C‒H 
Amination via Ring-Opening Cyclization Strategy to 
Quinazolin-4-ones: Development and Application in 
Rutaecarpine Synthesis 
 
 
  III. 1. INTRODUCTION: 
 
Quinazolinone is an important N–heterocyclic scaffold, as of their abundance in 
biologically active compounds and numerous natural products such as rutaecarpine,1 
tryptanthrin,2 luotonin A, B, E and F3 and bio active compounds (Figure 1). Owing 
to the promising biological & medicinal activities including anticancer,4 anti-
inflammatory,5 antibacterial,6 antihypertensive7 properties, synthetically 
quinazolinone scaffolds have been highly in demand and remains a challenge in 
organic synthesis.  The direct functionalization of C–H bonds of organic compounds 
has recently emerged as a diverse atom economic carbon–heteroatom (C–X)8 and 
carbon–carbon (C–C) bond formation.9  Several diverse C–H functionalization 
methodologies without prefunctionalization of the coupling partners have been 
widely developed in the past decades.10 Previously, we have employed N-
incorporation strategy for the synthesis of quinoxalines via dual C(sp2)-H 
functionalization11a and also, in recent past reported on the direct cycloaminative 
approach to imidazole derivatives via dual C-H functionalization.11b  
Over the past three decades, considerable progress has been made in the 
development of methods to construct sp2 carbon–nitrogen (C–N) bonds using 
palladium, copper or nickel catalysis. However, formation of sp3 C–N bonds 
remains one of the major challenges in the field of cross-coupling chemistry. 
Recently, much attention has been focused towards the development of transition-
metal catalyzed intramolecular C–H amination strategies to assemble N–
Heterocyclic compounds.12 In most of the cases, a tertiary amine has been used as 
one of the partner whereas α-C‒H bond has been activated. Application of this 
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strategy in intramolecular C‒heteroatom bond formation to synthesize challenging 
hetero cycles and pharmaceutically important compounds is less studied. Newly 
established methodology leading to the natural products are high demand for 
modern organic synthesis.14    
In this context, we are pleased to report intramolecular cross-dehydrogenative 
coupling C‒N bond formation under aerobic conditions for the synthesis of 
quinazolin-4(3H)-ones from isatoic anhydride and amines (benzylic & aliphatic) 
with copper (I) catalyst via ring opening cyclisation (ROC) strategy (Scheme 1). 
During this process an iminium ion intermediate formation, which is subsequently 
trapped by an amine nucleophile.   
Rutaecarpine, belongs quinazolinecarboline alkaloids isolated from fruits of Evodia 
rutaecarpa, a plant used for treatment of headache, cholera,  
and dysentery in Chinese medicine. Due to the medicinal importance of this 
alkaloid, various synthetic routes have been developed.15 Recently Jieping Zhu et al. 
synthesized rutaecarpine and (+)-evodiamine by a silver salt-catalyzed insertion of 
the isocyano group into the N-H bond of the tryptamine followed by in situ 
lactamization.16 Herein, we described the shorter route to rutaecarpine from 
isatoicanhydride and tryptoline via ROC strategy.    
 
 
 
Figure 1. Quinazolinone skeleton containing natural products. 
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III. 2. BACKGROUND: 
 
       III. 2.1. Intramolecular C-H amination: 
 
Fu and co-workers developed a simple method for the synthesis of 
quinazolinones via Cu-catalyzed oxidative dehydrogenation (Scheme 1).17 The 
reaction of substituted 2-halobenzamides and benzylamines using CuBr as the 
catalyst and air as an oxidant provided quinazolinones in moderate to good yields. 
 
Scheme 1 
Tang, Y.-L. et all, The quinazolinones were prepared by using α-substituted 
arylmethanamines  as starting materials instead of benzylamines. This reaction 
proceeds through a Cu-catalyzed domino reaction involving C-C bond cleavage 
(Scheme 2)18. 
 
 
      Scheme 2 
 
Cu-catalyzed oxidative dehydrogenation was described by Zou, Zhang, and co-
workers. The Cu-catalyzed reaction of 2-(2-halophenyl)-1H-indoles and 
benzylamines using air as an oxidant provided indolo[1,2-c]quinazolines (Scheme 
3)19. 
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Scheme 3 
 
 
Hua Fu and co-workers developed the synthesis of tetrahydroisoquinolino-[2,1-
a]quinazolinones from the reaction of N-substituted benzamides and 1,2,3,4-
tetrahydroisoquinolines (Scheme 4)20.  
 
 
Scheme 4 
In 2010, Maiti. D reported recently copper-catalysed C(sp3-H 
functionalization/cyclisation of 2-amino-N,N-dialkylbezamides for the synthesis 
of 2,3-disubstituted-4(3H)-quinazolinone derivatives (Scheme 5) 13. 
 
 
 
                                                                Scheme 5 
III. 2.2. Rutaecarpine Synthesis: 
 
Manojit Pal and co-workers reported A dual reactant/catalyst role of glyoxylic 
acid in the reaction of isatoic anhydride with various amines afforded a novel, 
robust and rapid synthesis of 3-(un)substituted quinazolin-4(3H)-ones. This method 
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has been successfully applied to the synthesis of quinazolinone alkaloid rutaecarpine 
(A) and evodiamine (B) (Scheme 6)1a. 
 
 
                                                                   Scheme 6 
Ming Li and co-workers reported A copper-catalyzed tandem arylation-
cyclization process to access 1-(arylthio)isoquinolines from isothiocyanates and 
diaryliodonium salts is described. This method has been successfully applied to the 
synthesis of quinazolinone alkaloid rutaecarpine (Scheme 7)21. 
 
 
Scheme 7 
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Copper-Catalyzed Intramolecular α-C‒H Amination via Ring-Opening 
Cyclization Strategy to Quinazolin-4-ones. And also this ROC strategy has been 
successfully applied to the synthesis of quinazolinone alkaloid rutaecarpine.        
 
 
        Scheme 1. Our present strategy for the synthesis of quinazolinone derivatives. 
 
        III. 3. Results and Discussion: 
Initially, we embarked on our study by examining the reaction of 25a in the 
presence of K2CO3 base and Cu(OAc)2 as the catalyst at 90 °C in DMSO, 2-
phenylquinazolin-4(3H)-one (26a) was afforded 45% yield (Table 1, entry 1). 
Further screening of various copper (II) and copper (I) catalyst could promote the 
reaction and CuBr was the optimal choice (Table 1, entries 1–6). 
To improve the yield of the product different bases were screened with CuBr, 
DMSO solvent obtained the product 25–68% yield at 90 oC (entries 7–10). Then we 
investigated the different solvents such as DMF, CH3CN, Toluene, DCE, and 
MeOH afforded 26a in lower yields (entries 11–15).  Among the solvents examined, 
DMSO exhibited the best transformation on giving the product 26a in 68% yield 
(entry 9). Upon conducting the reaction under argon instead of oxygen, the reaction 
yield decreased to 62% (entry 16). Next, we screened the reaction by varying the 
temperatures at 80 oC, 100 oC and 120 oC, we could obtain the product 26a in 70 % 
yield at 100 oC (entries 17–19). When reaction run in the absence of CuBr afforded 
26a in diminish yield, while absence of KOtBu reaction product did not firmed, so 
that this experiments indicates that copper and base were pivotal for the reaction 
(entries 20, 21).   
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Table 1. Optimization of Reaction Conditionsa  
 
 
 
 
           aReaction conditions: 25a (0.22 mmol), base (0.44 mmol) and 1 mL of solvent under O2 
for 2 h; 
b Isolated yields after column chromatography; cReaction was performed under 
argon; n.d = not detected. 
S.No. Catalyst Base Solvent Tempt (oC) Yield (%)b 
1 Cu(OAc)2 K2CO3 DMSO 90  45 
2 CuBr2 K2CO3 DMSO 90  49 
3 CuI K2CO3 DMSO 90  52 
4 CuBr K2CO3 DMSO 90  55 
5 Cu2O K2CO3 DMSO 90 50 
6 CuBr K2CO3 DMSO 90  58 
7 CuBr NaOtBu DMSO 90  62 
8 CuBr KOtBu DMSO 90  68 
9 CuBr NEt3 DMSO 90  25 
10 CuBr KOtBu DMF 90  62 
11 CuBr KOtBu CH3CN 90 60 
12 CuBr KOtBu Toluene 90 n.d 
13 CuBr KOtBu DCE 90 n.d 
14 CuBr KOtBu MeOH 90 n.d 
15 CuBr KOtBu DMSO 90 62c 
16 CuBr KOtBu DMSO 90 64d 
17 CuBr KOtBu DMSO 80 61 
18 CuBr KOtBu DMSO 100 70 
19 CuBr KOtBu DMSO 120 60 
20 - KOtBu DMSO 100 10 
21 CuBr - DMSO 100 0 
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With the optimized reaction conditions in hand, the scope of the reaction was 
investigated by varying both the benzyl amines and the isatoic anhydrides as shown 
in Table 2. The electronic effect on 2-amino-N-benzylbenzamides exerted no 
obvious influence upon the reaction. For example, the electron rich 2-amino-N-
benzylbenzamides showed good reactivity to afford the corresponding quinazolin-
4(3H)-ones (26a–26d) in 62–66% yields. At the same time, the 2-amino-N-
benzylbenzamides with electron-withdrawing substituents, including –F, –Cl 
participated in the reaction smoothly afforded the products 26e–26g in 56–60% 
yield. The relative sinking product formation observed upon varying substituents at 
the 5-position of 2-amino-N-benzylbenzamide deactivate the amine nucleophilicity, 
thereby decreasing the efficiency of the cyclization reaction considerably (26h–26m 
45-62%). 
Table 2. Scope of Isatoic anhydrides and aromaticamines. 
 
aReaction conditions: 25a (0.22 mmol), CuBr (15 mol %), KOtBu (2 equiv), DMSO (1 mL), 
O2, 100 oC.  
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      The structure of the 4b was confirmed by X-ray crystal structure analysis (Fig. 
2) (CCDC 1574127).   
  
 
 
 
 
 
Figure 2. X-ray crystal structure of product 4b. Thermal ellipsoids are drawn at 
30% probability level.  
To our delight, 2-amino-N-alkylbenzamide derivatives synthesized from 
aliphatic primary amines such as n-propyl and n-butyl also underwent 
intramolecular α-C‒H amination giving the products 26n and 26o in good yields. 
Contrarily, isopropyl amine provided unexpected product 2-methylquinazolin-
4(3H)-one 26p by C–C bond cleavage.22 Differently, cyclohexyl amine afforded the 
1'H-spiro[cyclohexane-1,2'-quinazolin]-4'(3'H)-one 26q in good yield under the 
standard reaction condition (Table 3, entries 26n‒26q 56-65%). 
Table 3. Scope of Isatoic anhydrides and aliphatic amines 
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After the successful synthesis of quinazolin-4(3H)-ones from isatoic anhydride and 
primary amines (benzyl and aliphatic), attempts to examine the site selectivity 
aspect of the ROC strategy, a number of unsymmetrical amides, which were 
synthesized by isatoic anhydride and unsymmetrical secondary amines (Table 4). In 
spite of having two possible N-methylene sites for cross dehydrogenative coupling 
C–N bond formation in 26r and 26s selectively undergoes cyclization only at the 
benzylic position in the presence of an N-methyl and N-ethyl moieties. And also, 
complete selectivity for C–N bond formation was observed at the benzylic side of 
tetrahydroisoquinoline while incorporated the 2-aminobenzamide (26t) and 2-
amino-5-chlorobenzamide (26u) (Table 4).  
Table 4. Cyclization with Unsymmetric Amines 
 
 
After having successful development of copper catalyzed intramolecular 
cyclization for the synthesis of quinazolin-4(3H)-ones 26 from 2-amino-N-
alkylbenzamide derivatives 25, subsequently we tested the N-methyl 
isatoicanhydride ring opening by benzylamine product 3 provide the 2-aryl-
quinazolinones by N–C bond cleavage along with the 1-methyl-2-phenylquinazolin-
4(1H)-one derivatives (Table 5, entries 26v–26x). Compare to C–H bond cleavage, 
N–C bond cleavage has been receiving much attention in organic chemistry, due to 
the inertness of this bond.23 To further rule out the demethylation, we performed a 
reaction in different solvents DMF and CH3CN, and also at low temperature 80 
oC 
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and 60 oC, which provided demethylation product along with expected product. On 
the basis of these experimental results, we proposed a reasonable mechanistic 
pathway. We have demonstrated a copper-catalyzed approach for the synthesis of 2-
substituted quinazolinones through an intramolecular N–C bond cleavage with air as 
the oxidant under basic conditions. 
 
Table 5. Substrate scope for the CuBr catalyzed synthesis of quinazolin-4(1H)-
one and quinazolin-4(3H)-one.a 
 
 
To probe the mechanism of intramolecular α-C‒H amination, preliminary 
control experiments were conducted whether the reaction proceeds through a radical 
pathway, we performed the standard reaction in the presence of radical scavengers 
like 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), ditert-butyl peroxide (DTP) and 
tert-butyl peroxybenzoate (TBPB) (Scheme 8). Which showed no significant 
decrease in the yield of the product 26a, and also did not observe any radical 
trapped intermediates. To further rule out the radical pathway, we performed a 
radical clock experiment under standard conditions, which provided 2-
cyclopropylquinazolin-4(3H)-one 26aa and no other ring-opened coupling products 
were observed (Scheme 9).  
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Scheme 8. Control Experiments 
 
 
Scheme 9: Radical Clock Exeperiment 
 
On the basis of the literature reports, and TEMPO/DTP/TBPB trapping 
experiments, a tentative ionic reaction mechanism was proposed. During the course 
of these reactions, an iminium ion as the key intermediate I in this transformation, 
subsequently the iminium ion underwent intramolecular cyclization followed by 
oxidation, to furnish the desired product 26a (Figure 2).    
 
Figure 2. Plausible reaction mechanism for the synthesis of quinazolin-4(3H)-one 26. 
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Having a developed copper-catalyzed rapid synthesis of 2-substituted 
quinazolin-4(3H)-ones, we were applied this ROC strategy for the synthesis of our 
target natural product rutaecarpine. Thus isatoic anhydride (1) was treated with 
tryptoline (2y) in DMSO solvent for 2 h give the desired product 3y. The compound 
3y on treatment with CuBr and KOtBu under oxygen at 100 oC afforded 
rutaecarpine (4y) in 60% yield.  And also we tried to apply this strategy for the 
synthesis of evodiamine but we failed to get expected product 4z. When we have 
treated 3z with CuBr and KOtBu under oxygen afforded rutaecarpine (4y) in 35% 
yield (Scheme 10).  
Scheme 10. Synthesis of Rutaecarpine 
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III. 4. Conclusion:  
In summary, we have developed a copper catalysed intramolecular α-C‒H 
amination of C(sp3)-H bond for the synthesis of quinazolin-4(3H)-one derivatives 
from commercially available isatoic anhydride and primary and secondary amines. 
This protocol, show good functional group tolerance and allow access to a range of 
2-alkyl, spiro and quinazolin-4(1H)-one derivatives by C‒C and N‒C bond cleavage 
in the progress of ROC strategy. It is the first general method to construct the 
potentially useful 2-methyl quinazolin-4(3H)-one by copper-catalyzed 
intramolecular C‒H amination. The synthetic utility of this strategy was illustrated 
by the convenient synthesis of rutaecarpine via ROC strategy. 
 
 
III. 5. Experimental Section 
 
General Considerations 
 
 
      IR spectra were recorded on a FTIR spectrophotometer. 1H NMR spectra were 
recorded on 400 MHz spectrometer at 295 K in CDCl3; chemical shifts (δ ppm) and 
coupling constants (Hz) are reported in standard fashion with reference to either 
internal standard tetramethylsilane (TMS) (δH = 0.00 ppm) or CHCl3 (δH = 7.25 
ppm). 13C NMR spectra were recorded on 100 MHz spectrometer at RT in CDCl3; 
chemical shifts (δ ppm) are reported relative to CHCl3 [δC = 77.00 ppm (central line 
of triplet)]. In the 1HNMR, the following abbreviations were used throughout: s = 
singlet, d = doublet, t = triplet, q = quartet, qui = quintet, m = multiplet and br s. = 
broad singlet. The assignments of signals were confirmed by 1H, 13C spectra. High-
resolution mass spectra (HR-MS) were recorded using Q-TOF multimode source.  
Melting points were determined on an electro thermal melting point apparatus and 
are uncorrected. 2-amino-N-benzylbenzamides (3) were prepared by using known 
procedures. All the dry solvents such as, MeOH, Toluene were dried over sodium 
metal and DMSO, CH3CN and DCE were dried over calcium hydride. 
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All small scale dry reactions were carried out using standard syringe-septum 
technique. Reactions were monitored by TLC on silica gel using a combination of 
petroleum ether and ethyl acetate as eluents. Reactions were generally run under an 
oxygen atmosphere. Solvents were distilled prior to use; petroleum ether with a 
boiling range of 40 to 60 ˚C was used.    
General Procedure 1: Preparation of 2-amino-N-benzylbenzamides: 
Isatoic anhydride (815 mg, 5 mmol) in Toluene was treated with benzylamine (547, 
5 mmol) at 100 °C for 1-2 h and monitored by TLC. After completion of the 
reaction, the mixture was washed with H2O and extracted with EtOAc. The organic 
layer was dried over anhydrous Na2SO4, concentrated in vacuum under reduced 
pressure and then purified by silica gel column chromatography using ethyl acetate 
and hexane (15/85) as eluents to afford the corresponding product 25 as a white 
solid (1.1 g, 98 % yield)24. 
General procedure 2: Preparation of 2-phenylquinazolin-4(3H)-ones through 
ROC Strategy: To a mixture of 2-amino-N-benzylbenzamides 25 (0.22 mmol), 
CuBr (15 mol %), and KOtBu (0.44 mmol) in a 10 mL Schlenk tube was added 2 
mL of DMSO, and the mixture was stirred at 100 °C for 2-4 h (monitored by TLC) 
under an oxygen balloon. After the completion of the reaction, the reaction mixture 
was cooled and was quenched with ice-cold water. Then the reaction mixture was 
extracted with ethyl acetate (3 × 10 mL). The combined organic extracts were 
washed with brine and dried with anhydrous Na2SO4. The crude extract was purified 
by filtration through a silica gel (100-200 mesh) column using hexane and ethyl 
acetate (8/2) as eluents to yield the desired quinazolinone products 26.  
 
 Spectroscopic data of all unknown compounds:  
  
2-phenylquinazolin-4(3H)-one (26a):  
 Physical State:White solid  
 Yield:(70 %  
Mp 140 oC;  
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 IR (MIR-ATR, 4000−600 cm-1): νmax = 3396, 1655, 1554, 1469, 995, 823, 762, 682, 
616;  
  
 1H NMR (400 MHz, CDCl3) δ ppm = 7.59−7.51 (m, 4H), 7.84−7.81 (m, 2H), 
8.35−8.27 (m, 3H), 11.81 (br. s, 1H). 
  
  13C NMR (100 MHz, CDCl3) δ ppm = 163.98, 151.81, 149.54, 134.93, 132.83, 
131.67, 129.05, 128.02, 127.46, 126.81, 126.38, 120.84. 
   
HR-MS (ESI+) m/z calculated for C14H10N2O [M + H
+] = 223.0866, found: 
223.0862. 
 2-(4-methoxyphenyl) quinazolin-4(3H)-one (26b):  
Physical State : White solid                                          
 Yield:65 % 
 Mp 232 oC;  
  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 1679, 1600, 1523, 1479, 1247, 1177, 1030, 
834, 764; 
  
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 3.8 (s, 3H), 6.93 (d, J = 8.8, 2H), 
7.35 (td, J = 7.3, 7.3, 1H), 7.69-7.63 (m, 2H), 8.14-8.10 (m, 3H); 
   
 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 162.16, 161.02, 151.08, 148.35, 
133.25, 128.41, 126.39, 124.19, 119.90, 112.92, 54.36. 
   
 HR-MS (ESI+) m/z calculated for C15H12N2O2 [M + H+] = 253.0972, found: 
253.0972. 
 2-(p-tolyl) quinazolin-4(3H)-one (26c):  
Physical State :White solid                               
Yield:62 % 
Mp. :262 oC 
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IR (MIR-ATR, 4000−600 cm-1): νmax = 3741, 1669, 1608, 1550, 1299, 941, 832, 
767, 730; 
  
1H NMR (400 MHz, CDCl3) δ ppm = 11.75 (br. s, 1H), 8.33 (d, J = 7.8, 1H), 8.16 
(d, J = 7.3, 2H), 7.81-7.79 (m, 2H), 7.49 (t, J = 7.1, 7.1, 1H), 7.37 (d, J = 7.8, 2H), 
2.46 (s, 3H). 
  
13C NMR (100 MHz, CDCl3) δ ppm = 164.00, 151.86, 149.64, 142.18, 134.84, 
129.98, 129.75, 127.9, 127.38, 126.56, 126.36, 120.78, 21.56. 
  
HR-MS (ESI+) m/z calculated for C15H12N2O [M + H
+] = 237.1022, found: 
237.1024. 
2-(2-methoxyphenyl) quinazolin-4(3H)-one (26d):  
Physical State :White solid 
Yield:58%                                                                     
 Mp :170 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax =3743, 1676, 1593, 1557, 1474, 1233, 1013, 
745. 
   
 1H NMR (400 MHz, CDCl3) δ ppm = 10.95 (br. s., 1H), 8.51 (dd, J = 7.83, 1.96 Hz, 
1H), 8.19 - 8.36 (m, 1H), 7.63 - 7.83 (m, 2H), 7.38 - 7.53 (m, 2H), 7.11 - 7.18 (m, 
1H), 7.04 (d, J = 8.31 Hz, 1H), 4.03 (s, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 161.89, 157.76, 150.77, 149.39, 134.45, 
133.17, 131.51, 127.85, 126.45, 126.39, 121.83, 121.18, 119.91, 111.81, 56.14. 
   
 HR-MS (ESI+) m/z calculated for C15H12N2O2 [M + H+] = 253.0972, found: 
253.0971. 
    
 2-(4-fluorophenyl) quinazolin-4(3H)-one (26e):  
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Physical State : White solid                                   
 Yield : 60%      
 Mp : 260 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3742, 1659, 1620, 1215, 755;  
  
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 12.09(br. s. 1H), 8.17 (dd, J = 8.1 
and 6.1, 2H), 7.69-7.67 (m, 2H), 7.39-7.34 (m, 2H), 7.14-7.10 (m, 2H). 
   
 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 163.31, 151.39 (d, JC-F = 227.0 
Hz), 149.13, 134.39, 130.03 (d, JC-F = 9.0 Hz), 129.94, 127.60, 126.06, 121.02, 
115.78 (d, JC-F = 22.0 Hz), 115.56. 
HR-MS (ESI+) m/z calculated for C14H9FN2O [M + H
+] = 241.0772, found: 
241.0777. 
2-(2-chlorophenyl) quinazolin-4(3H)-one (26f): 
Physical State : White solid 
Yield : 66%                                                                                        
 Mp : 55 oC.  
           
IR (MIR-ATR, 4000−600 cm-1): νmax = 3743, 1666, 1605, 1559, 1512, 1474, 1334, 
1292, 768, 690. 
  
1H NMR (400 MHz, CDCl3) δ ppm = 11.87 (br. s. 1H), 8.35-8.29 (m, 1H), 8.28-
8.27 (m, 2H), 7.85-7.81 (m, 2H), 7.61-7.59 (m, 2H), 7.53-7.49 (m, 1H). 
 
 13C NMR (100 MHz, CDCl3) δ ppm = 163.99, 151.79, 149.55, 134.92, 132.83, 
131.66, 129.05, 128.02, 127.46, 126.80, 126.37, 120.85. 
   
 HR-MS (ESI+) m/z calculated for C14H9ClN2O [M + H+] = 257.0476, found: 
257.0480. 
2-(4-chlorophenyl) quinazolin-4(3H)-one (26g):  
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 Physical State :White solid 
Yield:56%                                                                
 Mp :200 oC;  
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3742, 1740, 1703, 1641, 1516, 1462, 1515, 
1240, 720;  
 
1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 12.49 (br. s. 1H), 8.25-8.18 (m, 
3H), 7.77-7.73 (m, 2H), 7.53-7.48 (m, 3H). 
 
 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 167.6, 156.3, 153.8, 141.8, 
139.3, 136.6, 134.5, 133.6, 133.5, 132.6, 131.5, 130.9, 126.2. 
 
HR-MS (ESI+) m/z calculated for C14H9ClN2O [M + H
+] = 257.0476, found: 
257.0476.   
 
6-chloro-2-phenylquinazolin-4(3H)-one (26h):  
Physical State :White solid                                                   
Yield:62%  
Mp :230 oC; 
  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3742, 2923, 1680, 1646, 1509, 1467, 1250, 
690. 
   
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 8.21-8.18 (m, 2H), 7.74-7.68 (m, 
2H), 7.55 (br. s. 1H), 7.36 (d, J = 5.9, 1H). 
  
 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 152.44, 147.35, 134.13, 132.33, 
131.17, 131.03, 129.06, 128.44, 128.21, 127.41, 124.91, 121.93. 
   
HR-MS (ESI+) m/z calculated for C14H9ClN2O [M+H
+] = 257.0476, found: 
257.0476. 
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 6-chloro-2-(4-methoxyphenyl) quinazolin-4(3H)-one (26i):  
Physical State :White solid 
 Yield:58 %                                                                   
 Mp :145 oC;  
  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3723, 1666, 1603, 1508, 1253, 1177, 1031, 
832. 
   
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 11.72 (br. s. 1H), 8.28-8.17 (m, 
2H), 7.76-7.68 (m, 2H), 7.39 (s, 1H), 7.03 (dd, J = 8.8 and 2.4, 2H), 3.89 (s, 1H).  
13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 163.36, 149.49, 134.66, 134.37, 
129.32, 129.20, 127.51, 126.11, 126.01, 125.47, 120.86, 114.10, 55.39. 
   
HR-MS (ESI+) m/z calculated for C15H11ClN2O2 [M+H
+] = 287.0582, found: 
257.0585. 
 6-chloro-2-(2-chlorophenyl) quinazolin-4(3H)-one (26j):  
Physical State : White solid                                                         
 Yield: 55 % 
Mp : 270 oC;  
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3394, 1678, 995, 824, 763. 
   
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 8.14-8.12 (m, 2H), 7.81 (s, 1H), 
7.65-7.7.48 (m, 2H), 7.45-7.7.43 (m, 2H). 
  
  13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 160.57, 151.46, 146.38, 133.15, 
131.37, 130.07, 128.17, 127.23, 126.52, 123.9, 121. 
   
 HR-MS (ESI+) m/z calculated for C16H8Cl2N2O [M+H+] = 291.0086, found: 
291.0076. 
6-chloro-2-(4-fluorophenyl) quinazolin-4(3H)-one (26k):  
106 
 
 Physical State :White solid                             
 Yield:56%  
 Mp :260 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3419, 1655, 1506, 1420, 1288, 1182, 1023, 
994, 825, 730.  
  
 H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 12.64 (br. s. 1H), 8.23 (dd, J = 8.6 
and 5.1, 2H), 8.08-8.05 (m, 1H), 7.74-7.67 (m, 2H), 7.24 (t, J = 8.3, 8.3 and 8.3, 
2H).  
  
 13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 161.41, 151.55 (d, JC-H = 422.0 
Hz), 147.32, 135.81, 134.34, 130.94, 130.1 (d, JC-H = 9.0 Hz), 129.31, 128.72, 
124.83, 115.45 (d, JC-H = 21.0 Hz), 115.24. 
   
 HR-MS (ESI+) m/z calculated for C14H8ClFN2O [M+H+] = 275.0382, found: 
275.0382. 
6-chloro-2-(p-tolyl) quinazolin-4(3H)-one (26l):                         
 Physical State :White solid 
 Yield:58 % 
 Mp 230 oC;  
  
 IR (MIR-ATR, 4000−600 cm-1): νmax = 2920, 1667, 1600, 1466, 1286, 762. 
  
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 12.46 (br. s. 1H), 8.20-8.09 (m, 
2H), 7.9 (d, J = 3.4, 1H), 7.76-7.73 (m, 2H), 731 (d, J = 6.8, 2H), 2.43 (s, 3H). 
   
13C NMR (100 MHz, CDCl3) δ ppm = 160.39, 140.22, 132.97, 129.62, 128.38, 
127.76, 126.31, 123.68, 120.75, 19.85 
.  
HR-MS (ESI+) m/z calculated for C15H11ClN2O [M+H
+] = 271.0633, found: 
271.0636. 
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6-chloro-2-(4-chlorophenyl) quinazolin-4(3H)-one (26m):  
Physical State :White solid;  
Yield:45 %                                                                                   
Mp :320 oC.    
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3391, 1659, 1021, 
997, 825, 763, 624. 
  
 1H NMR (400MHz, DMSO-d6) = 12.77 (br.s. 1H), 8.31 - 8.13 (m, 2H), 8.09 (s, 1H), 
7.95 - 7.82 (m, 1H), 7.77 (d, J = 8.8 Hz, 1 H), 7.68 - 7.54 (m, 2H). 
   
 13C NMR (100 MHz, DMSO-d6) δ ppm = 176.20, 142.93, 136.49, 134.75, 131.26, 
130.95, 129.67, 128.70, 128.62, 128.27, 127.81, 124.86. 
 HR-MS (ESI+) m/z calculated for C14H8Cl2N2O [M+H+] = 291.0086, found: 
271.0089. 
2-ethylquinazolin-4(3H)-one (26n):  
Physical State :White solid                                            
 Yield:56 %   
 Mp :210 oC; 
  
  IR (MIR-ATR, 4000−600 cm-1): νmax = 3841, 1682, 1586, 1420, 1234, 1181, 774, 
756, 692. 
  
 1H NMR (400 MHz, CDCl3) δ ppm = 12.23 (br. s., 1H), 8.30 (dd, J = 8.07, 1.22 Hz, 
1H), 7.60 - 7.86 (m, 2H), 7.33 - 7.60 (m, 1H), 2.86 (q, J = 7.34 Hz, 2H), 1.47 (t, J = 
7.58 Hz, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 164.57, 157.79, 149.53, 134.81, 127.22, 
126.36, 126.24, 120.50, 29.17, 11.60.  
 HR-MS (ESI+) m/z calculated for C10H10N2O [M+H+] = 175.0866, found: 175.0865. 
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 2-propylquinazolin-4(3H)-one (26o):  
Physical State :White solid                                                      
 Yield:60%    
 Mp 180 oC; 
  
  IR (MIR-ATR, 4000−600 cm-1): νmax = 3641, 1686, 1556, 1410, 1209, 1191, 776, 
766, 698. 
 1H NMR (400 MHz, CDCl3) δ ppm = 12.24 (br. s., 1H), 8.30 (dd, J = 8.07, 1.22 Hz, 
1H), 7.59 - 7.87 (m, 2H), 7.39 - 7.56 (m, 1H), 2.66 - 2.88 (m, 2H), 1.94 (dq, J = 
15.10, 7.52 Hz, 2H), 1.09 (t, J = 7.34 Hz, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 164.53, 156.89, 149.53, 134.79, 127.22, 
126.21, 120.48, 37.74, 21.05, 13.77.  
 HR-MS (ESI+) m/z calculated for C11H12N2O [M+H+] = 189.1022, found: 189.1022. 
   
 2-methylquinazolin-4(3H)-one (26p):  
Physical State : White solid 
 Yield: 57%                                                                                  
 Mp  : 280 oC;    
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3346, 1586, 1456, 1310, 1109, 991, 778, 
798, 688.  
 1H NMR (400MHz, DMSO-d6) δ ppm = 12.21 (br. s., 1H), 7.99 - 8.16 (m, 1H), 7.72 
- 7.85 (m, 1H), 7.48 - 7.60 (m, 1H), 7.44 (t, J = 7.58 Hz, 1H), 3.42 (s, 3H). 
   
 13C NMR (100 MHz, DMSO-d6) δ ppm = 161.71, 154.24, 145.36, 134.27, 126.7, 
125.8, 125.63, 120.56, 21.39. 
 HR-MS (ESI+) m/z calculated for C9H8N2O [M+H+] = 161.0709, found: 161.0709. 
 
  
 1'H-spiro[cyclohexane-1,2'-quinazolin]-4'(3'H)-one (26q):  
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 Physical State :White solid 
 Yield: 65%                                  
 Mp :140 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3324, 3040, 1679, 1580, 1486, 1392, 1182, 
1120, 982, 776, 723, 685. 
  
  1H NMR (400MHz , CDCl3) δ ppm = 11.29 (br. s., 1H), 8.28 (dd, J = 1.2, 8.1 Hz, 
1H), 7.86 - 7.60 (m, 2H), 7.58 - 7.36 (m, 1H), 2.83 - 2.71 (m, 2H), 2.28 - 2.10 (m, 
1H), 2.10 - 1.93 (m, 1H), 1.91 - 1.78 (m, 3H), 1.01 - 0.84 (m, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 163.86, 156.74, 134.81, 127.22, 126.40, 
126.26, 36.01, 31.38, 27.22, 22.35, 13.94 
 .  
 HR-MS (ESI+) m/z calculated for C13H16N2O [M+H+] = 217.1335, found: 217.1328. 
   
 3-methyl-2-phenylquinazolin-4(3H)-one (26r):  
 Physical State :White Solid  
 Yield:63%                                                        
 Mp :132 oC; 
   
 IR (MIR-ATR, 4000–600 cm-1): v max = 1673, 1562, 1472, 1352, 1023, 773, 641; 
   
 1H NMR (400 MHz, CDCl3) δ ppm = 8.33 (d, J = 8.31 Hz, 1H), 7.71 - 7.81 (m, 2H), 
7.45 - 7.61 (m, 6H), 3.50 (s, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 162.73, 156.14, 147.33, 135.42, 134.32, 
130.08, 128.90, 127.51, 127.01, 126.69, 120.54, 34.28. 
   
 HR-MS (ESI+) m/z calculated for C15H12N2O [M+H+] = 237.1022, found: 237.1030. 
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 3-ethyl-2-phenylquinazolin-4(3H)-one (26s):  
 Physical State :White Solid                                                        
 Yield:62%    
 Mp 125 oC; 
   
 IR (MIR-ATR, 4000–600 cm-1): vmax = 1673, 1564, 1468, 1378, 1254, 1066, 772, 
701; 
  
  1H NMR (400 MHz, CDCl3) δ ppm = 8.34 (d, J = 7.34 Hz, 1H), 7.64 - 7.94 (m, 
2H), 7.37 - 7.63 (m, 6H), 4.04 (d, J = 6.85 Hz, 2H), 1.22 (t, J = 7.09 Hz, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 162.01, 156.20, 147.21, 135.62, 134.29, 
129.79, 128.82, 127.67, 127.46, 126.95, 126.71, 121.00, 41.19, 14.12. 
  
  HR-MS (ESI+) m/z calculated for C16H14N2O [M+H+] = 251.1179, found: 251.1185. 
  
 5H-isoquinolino[1,2-b] quinazolin-8(6H)-one (26t):  
 Physical State :White Solid;  
 Yield:58%;  
 Mp :140 oC;    
   
 IR (MIR-ATR, 4000–600 cm-1): vmax = 1670, 1558, 1475, 1394, 1335, 1150, 768, 
707.  
  
 1H NMR (400 MHz, CDCl3) δ ppm = 8.49 (dd, J = 7.82, 1.47 Hz, 1H), 8.27 - 8.39 
(m, 1H), 7.70 - 7.84 (m, 2H), 7.38 - 7.57 (m, 3H), 7.22 - 7.34 (m, 1H), 4.33 - 4.48 
(m, 2H), 3.11 (t, J = 6.60 Hz, 2H).  
  
 13C NMR (100 MHz, CDCl3) δ ppm = 161.74, 149.40, 147.84, 137.07, 134.23, 
131.73, 129.6, 128.05, 127.65, 127.63, 127.51, 126.88, 126.54, 120.78, 39.63, 
27.49. 
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 HR-MS (ESI+) m/z calculated for C16H12N2O [M+H+] = 249.1022, found: 249.1028. 
  
 10-chloro-5H-isoquinolino[1,2-b] quinazolin-8(6H)-one (26u):  
 Physical State :White Solid;                                  
 Yield: 55%  
 Mp 172 oC;     
   
 IR (MIR-ATR, 4000–600 cm-1): vmax = 1672, 1555, 1466, 1394, 1335, 1240, 1153, 
1067, 895, 833, 772. 
  
  1H NMR (400 MHz, CDCl3) δ ppm = 8.46 (d, J = 7.34 Hz, 1H), 8.27 (d, J = 1.96 
Hz, 1H), 7.61 - 7.81 (m, 2H), 7.39 - 7.56 (m, 2H), 7.19 - 7.35 (m, 1H), 4.32 - 4.52 
(m, 2H), 3.11 (t, J = 6.60 Hz, 2H).  
 13C NMR (100 MHz, CDCl3) δ ppm = 160.75, 149.63, 146.33, 137.03, 134.70, 
132.21, 131.98, 129.27, 128.05, 127.72, 127.59, 126.22, 121.70, 39.77, 27.36. 
   
 HR-MS (ESI+) m/z calculated for C16H11ClN2O [M+H+] = 283.0633, found: 
283.0633. 
  
 1-methyl-2-phenylquinazolin-4(1H)-one (26v):  
 Physical State :Brown solid;                                      
 Yield: 34%   
 Mp :210 oC;  
   
 IR (MIR-ATR, 4000–600 cm-1): v max = 1640, 1602, 1519, 1458, 1393, 1257, 1144, 
1071, 1036, 765, 699. 
  
 1H NMR (400 MHz, CDCl3) δ ppm = 8.42 (dd, J = 7.82, 1.47 Hz, 1H), 7.73 - 7.88 
(m, 1H), 7.59 - 7.69 (m, 2H), 7.44 - 7.59 (m, 5H), 3.73 (s, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 168.79, 162.49, 141.82, 134.76, 133.94, 
130.73, 128.88, 128.74, 128.65, 126.27, 120.41, 115.20, 37.98. 
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 HR-MS (ESI+) m/z calculated for C15H12N2O [M+H+] = 237.1022, found: 237.1027. 
    
  
 2-phenylquinazolin-4(3H)-one (26v’):                  
 Physical State :White Solid 
Yield: 38%  
 Mp 142 oC;  
   
 IR (MIR-ATR, 4000–600 cm-1): v max = 3396, 1655, 1554, 1469, 995, 823, 762, 682, 
616;  
 1H NMR (400MHz, DMSO-d6) = 12.56 (br. s., 1H), 8.10 - 8.25 (m, 3H), 7.80 - 7.89 
(m, 1H), 7.70 - 7.80 (m, 1H), 7.37 - 7.62 (m, 4H). 
  
  13C NMR (100 MHz, DMSO-d6) δ ppm = 162.21, 152.26, 148.70, 134.57, 132.67, 
131.36, 128.57, 127.73, 127.47, 126.55, 125.82, 120.94. 
   
 HR-MS (ESI+) m/z calculated for C14H10N2O [M + H+] = 223.0866, found: 
223.0862. 
 1-methyl-2-(p-tolyl) quinazolin-4(1H)-one (26w):               
 Physical State :Yellow solid;  
 Yield: 32%   
  Mp :165 oC; 
  
  IR (MIR-ATR, 4000–600 cm-1): v max = 1688, 1619, 1514, 1464, 1418, 1286, 1041, 
967, 785, 674;  
   
 1H NMR (400 MHz, CDCl3) δ ppm = 8.38 (d, J = 7.82 Hz, 1H), 7.66 - 7.85 (m, 1H), 
7.43 - 7.60 (m, 5H), 7.21 - 7.36 (m, 2H), 3.73 (s, 3H), 2.43 (s, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 168.87, 162.60, 141.93, 141.15, 133.81, 
131.85, 129.22, 129.03, 128.59, 126.08, 120.36, 115.24, 38.12, 21.50. 
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 HR-MS (ESI+) m/z calculated for C16H14N2O [M + H+] = 251.1179, found: 
251.1178. 
 2-(p-tolyl) quinazolin-4(3H)-one (26w’):  
 Physical State :White Solid;                                
 Yield: 30%   
 Mp 150 oC;  
   
 IR (MIR-ATR, 4000–600 cm-1): vmax = 3742, 1672, 1605, 1556, 1473, 1294, 767, 
686.  
 1H NMR (400 MHz, CDCl3) δ ppm = 11.68 (br. s., 1H), 8.22 - 8.43 (m, 1H), 8.16 
(m, J = 8.31 Hz, 2H), 7.76 - 7.85 (m, 2H), 7.49 (ddd, J = 7.95, 6.24, 1.96 Hz, 1H), 
7.37 (m, J = 7.83 Hz, 2H), 2.46 (s, 3H). 
   
 13C NMR (100 MHz, CDCl3) δ ppm = 163.96, 151.83, 149.66, 142.18, 134.83, 
130.00, 129.75, 128.07, 127.91, 127.36, 126.55, 126.37, 120.79, 21.55. 
   
 HR-MS (ESI+) m/z calculated for C15H12N2O [M + H+] = 237.1022, found: 
237.1026.     
 2-(4-fluorophenyl)-1-methylquinazolin-4(1H)-one (26x):  
 Physical State :White Solid; 
 Yield: 29%  
 Mp :210 oC;  
   
 IR (MIR-ATR, 4000–600 cm-1): vmax = 1640, 1493, 1455, 1394, 1225, 1147, 856, 
766, 695; 
   
 1H NMR (400 MHz, CDCl3) δ ppm = 8.33 (dd, J = 7.82, 1.47 Hz, 1H), 7.76 (ddd, J 
= 8.44, 7.21, 1.47 Hz, 1H), 7.61 - 7.69 (m, 2H), 7.42 - 7.53 (m, 2H), 7.12 - 7.21 (m, 
2H), 3.72 (s, 3H).  
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 13C NMR (100 MHz, CDCl3) δ ppm = 168.65, 161.47 (d, JC-H = 381.0 Hz), 141.79, 
133.97, 131.35 (d, JC-H = 8.0 Hz), 130.85, 128.59, 126.32, 120.33, 115.95 (d, JC-H = 
22.0 Hz), 115.29, 38.08. 
   
 HR-MS (ESI+) m/z calculated for C15H11FN2O [M + H+] = 255.0928, found: 
255.0921.  
  
 2-(4-fluorophenyl) quinazolin-4(3H)-one (26x’): 
 Physical State: White solid  
 Yield:32%  
 Mp :260 oC; 
   
 IR (MIR-ATR, 4000−600 cm-1): νmax = 3742, 1659, 1620, 1215, 755; 
  
 1H NMR (400 MHz, CDCl3 + DMSO-d6) δ ppm = 12.09 (br. s. 1H), 8.17 (dd, J = 
8.1 and 6.1, 2H), 7.69-7.67 (m, 2H), 7.39-7.34 (m, 2H), 7.14-7.10 (m, 2H). 
  
13C NMR (100 MHz, CDCl3 + DMSO-d6) δ ppm = 163.31, 151.39 (d, JC-F = 227.0 
Hz), 149.13, 134.39, 130.03 (d, JC-F = 9.0 Hz), 129.94, 127.60, 126.06, 121.02, 
115.78 (d, JC-F = 22.0 Hz), 115.56. 
HR-MS (ESI+) m/z calculated for C14H9FN2O [M + H
+] = 241.0772, found: 
241.0777. 
2,3,4,9-tetrahydro-1H-pyrido[3,4-b] indole (26y):     
 Physical State :Brown solid; 
 Yield:72%   
Mp :152 oC;   
  
IR (MIR-ATR, 4000−600 cm-1): νmax = 3743, 3648, 1731, 1642, 1515, 1462, 1287, 
801, 668; 
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1H NMR (400 MHz, CDCl3) δ ppm = 7.91 (br. s., 1H), 7.48 (d, J = 7.34 Hz, 1H), 
7.20 - 7.38 (m, 1H), 7.04 - 7.18 (m, 2H), 4.00 (s, 2H), 3.17 (t, J = 5.62 Hz, 2H), 2.75 
(t, J = 5.38 Hz, 2H).  
13C NMR (100 MHz, CDCl3) δ ppm = 135.66, 132.74, 127.57, 121.47, 119.37, 
117.86, 110.70, 108.66, 43.86, 43.16, 22.45. 
  
HR-MS (ESI+) m/z calculated for C11H12N2 [M + H
+] = 173.1073, found: 173.1073.  
      
7,8-dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one (26z) :  
Physical State : White solid                
Yield: 60%  
Mp : 136 oC.                
 
IR (MIR-ATR, 4000−600 cm-1): νmax = 1613, 1590, 1469, 1435, 1307, 1234, 1159, 
736, 698.  
1H NMR (400 MHz, CDCl3 ) δ ppm = 9.95 (br. s., 1H), 8.33 (dd, J = 8.07, 1.22 Hz, 
1H), 7.54 - 7.83 (m, 3H), 7.41 (ddd, J = 8.19, 6.72, 1.71 Hz, 1H), 7.26 (dd, J = 5.14, 
1.71 Hz, 2H), 7.15 (ddd, J = 8.07, 4.65, 3.42 Hz, 1H), 4.51 - 4.68 (m, 2H), 3.22 (t, J 
= 6.85 Hz, 2H).  
13C NMR (100 MHz, CDCl3) δ ppm = 161.63, 147.41, 145.20, 138.38, 134.42, 
127.29, 127.12, 126.49, 126.26, 125.57, 121.15, 120.59, 120.08, 118.49, 112.16, 
41.18, 19.68. 
  
HR-MS (ESI+) m/z calculated for C18H13N3O [M + H
+] = 288.1131, found: 
288.1136.  
    
2-cyclopropylquinazolin-4(3H)-one (26aa): 
Physical State : White solid                                   
Yield : 63 
 Mp : 230 oC;   
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IR (MIR-ATR, 4000−600 cm-1): νmax = 2922, 2057, 1669, 1604, 1459, 1395, 981, 
893, 763, 606. 
1H NMR (400 MHz, CDCl3) δ ppm = 11.66 (br. s, 1H), 8.26 (d, J = 7.8, 1H), 7.72 (t, 
J = 7.3, 7.3, 1H), 7.6 (d, J = 8.3, 1H), 2.03-1.92 (m, 1H), 1.36-1.28 (m, 2H), 1.16-
1.1 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ ppm = 163.97, 157.96, 149.82, 134.65, 127.01, 
126.28, 125.66, 120.5, 34.01, 14.72, 9.62 
   
Elem. Anal. Calc. for C11H10N2O (186.0793): C, 70.95; H, 5.41; N, 15.04; found C, 
70.45; H, 5.62; N, 15.48. 
 
 
 
 
 
 
 
Figure 1. X-ray crystal structure of product 26b (CCDC 1574127). Thermal ellipsoids are 
drawn at 30% probability level.  
 
Operator Jayeetha Bhattacharjee  
Difractometer Oxford Super Nova                   
Empirical formula C15H12N2O2  
Formula weight 252.27  
Temperature/K 150(2)  
Crystal system monoclinic  
Space group P21/n  
a/Å 10.4890(11)  
b/Å 5.0325(4)  
c/Å 22.9271(16)  
α/° 90.00  
β/° 97.654(7)  
       γ/° 90.00  
Volume/Å3 1199.46(18)  
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Z 4  
ρcalcg/cm3 1.397  
μ/mm-1 0.095  
F(000) 528.0  
Crystal size/mm3 0.2 × 0.1 × 0.1  
Radiation Mo Kα (λ = 0.7107)  
2Θ range for data collection/° 6.22 to 58.22  
Index ranges -12 ≤ h ≤ 13, -6 ≤ k ≤ 5, -31 ≤ l ≤ 27  
Reflections collected 5189  
Independent reflections 2761 [Rint = 0.0308, Rsigma = 0.0626]  
Data/restraints/parameters 2761/0/173  
Goodness-of-fit on F2 0.988  
Final R indexes [I>=2σ (I)] R1 = 0.0611, wR2 = 0.1570  
Final R indexes [all data] 
 
R1 = 0.1061, wR2 = 0.2049 
 
 
Largest diff. peak/hole / e Å-3 0.19/-0.27  
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Figure 1.  1H NMR (400 MHz) spectrum of compound 26a in CDCl3. 
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Figure 2.  13C NMR (100 MHz) spectrum of compound 26a in CDCl3. 
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Figure 3.  1H NMR (400 MHz) spectrum of compound 26b in CDCl3 + DMSO-d6. 
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Figure 4.  13C NMR (100 MHz) spectrum of compound 26b in CDCl3 + DMSO-d6.  
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Figure 5.  1H NMR (400 MHz) spectrum of compound 26c in CDCl3 
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Figure 6.  13C NMR (100 MHz) spectrum of compound 26c in CDCl3.  
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Figure 7.  1H NMR (400 MHz) spectrum of compound 26d in CDCl3 
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Figure 8.  13C NMR (100 MHz) spectrum of compound 26d in CDCl3. 
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Figure 9.  1H NMR (400 MHz) spectrum of compound 26e in CDCl3 + DMSO-d6 
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Figure 10.  13C NMR (100 MHz) spectrum of compound 4e in CDCl3 + DMSO-d6. 
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Figure 11.  1H NMR (400 MHz) spectrum of compound 26f in CDCl3 
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Figure 12.  13C NMR (100 MHz) spectrum of compound 26f in CDCl3. 
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Figure 13.  1H NMR (400 MHz) spectrum of compound 26g in CDCl3 + DMSO-d6 
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Figure 14.  13C NMR (100 MHz) spectrum of compound 26g in CDCl3 + DMSO-d6. 
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Figure 15.  1H NMR (400 MHz) spectrum of compound 26h in CDCl3 + DMSO 
d6.
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Figure 16. 13C NMR (100 MHz) spectrum of compound 26h in CDCl3 + DMSO-d6. 
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Figure 17.  1H NMR (400 MHz) spectrum of compound 26i in CDCl3 + DMSO-d6. 
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Figure 18.  13C NMR (100 MHz) spectrum of compound 26i in CDCl3 + DMSO-d6. 
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Figure 19.  1H NMR (400 MHz) spectrum of compound 26j in CDCl3 + DMSO-d6. 
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Figure 20.  13C NMR (100 MHz) spectrum of compound 26j in CDCl3 + DMSO-d6. 
 
128 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
2.011.911.592.02
8
.2
4
8
.2
3
8
.2
2
8
.2
1
8
.0
8
8
.0
6
8
.0
5
7
.7
2
7
.7
1
7
.6
9
7
.2
6
7
.2
4
7
.2
2
3
.4
6
3
.4
0
2
.5
0
1
.2
0
-0
.0
5
 
Figure 21.  1H NMR (400 MHz) spectrum of compound 26k in CDCl3 + DMSO-d6 
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Figure 22.  13C NMR (100 MHz) spectrum of compound 26k in CDCl3 + DMSO-d6. 
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Figure 23.  1H NMR (400 MHz) spectrum of compound 26l in CDCl3 + DMSO-d6. 
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Figure 24.  13C NMR (100 MHz) spectrum of compound 26l in CDCl3 + DMSO-d6.. 
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Figure 25.  1H NMR (400 MHz) spectrum of compound 26m in DMSO-d6. 
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Figure 26.  13C NMR (100 MHz) spectrum of compound 26m in DMSO-d6 
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Figure 27.  1H NMR (400 MHz) spectrum of compound 26n in CDCl3 
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Figure 28.  13C NMR (100 MHz) spectrum of compound 26n in CDCl3. 
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Figure 29.  1H NMR (400 MHz) spectrum of compound 26o in CDCl3 
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Figure 30.  13C NMR (100 MHz) spectrum of compound 26o in CDCl3. 
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Figure 31.  1H NMR (400 MHz) spectrum of compound 26p in DMSO-d6. 
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Figure 32.  13C NMR (100 MHz) spectrum of compound 26p in DMSO-d6. 
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Fi
gure 33.  1H NMR (400 MHz) spectrum of compound 26q in CDCl3 
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Figure 34.  13C NMR (100 MHz) spectrum of compound 26q in CDCl3. 
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Figure 35.  1H NMR (400 MHz) spectrum of compound 26r in CDCl3 
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Figure 36.  13C NMR (100 MHz) spectrum of compound 26r in CDCl3. 
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Figure 37.  1H NMR (400 MHz) spectrum of compound 26s in CDCl3 
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
1
6
2
.0
1
1
5
6
.2
0
1
4
7
.2
1
1
3
5
.6
2
1
3
4
.2
9
1
2
9
.7
9
1
2
8
.8
2
1
2
7
.6
7
1
2
7
.4
6
1
2
6
.9
5
1
2
1
.0
0
7
7
.3
8
7
7
.0
6
7
6
.7
5
4
1
.2
0
1
4
.1
2
 
Figure 38.  13C NMR (100 MHz) spectrum of compound 26s in CDCl3. 
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Figure 39.  1H NMR (400 MHz) spectrum of compound 26t in CDCl3 
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Figure 40.  13C NMR (100 MHz) spectrum of compound 26t in CDCl3. 
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Figure 41.  1H NMR (400 MHz) spectrum of compound 26u in CDCl3 
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Figure 42.  13C NMR (100 MHz) spectrum of compound 26u in CDCl3. 
139 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
3.205.552.231.161.00
8
.4
4
8
.4
1
7
.8
0
7
.6
5
7
.6
4
7
.6
3
7
.5
4
7
.5
3
7
.5
2
7
.5
2
7
.5
1
3
.7
3
0
.0
0
 
Figure 43.  1H NMR (400 MHz) spectrum of compound 26v in CDCl3 
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Figure 44.  13C NMR (100 MHz) spectrum of compound 26v in CDCl3. 
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Figure 45.  1H NMR (400 MHz) spectrum of compound 26v’ in CDCl3 + DMSO-
d6.
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
6
2
.2
1
1
5
2
.2
6
1
4
8
.7
0
1
3
4
.5
7
1
3
2
.6
8
1
3
1
.3
6
1
2
8
.5
7
1
2
7
.7
3
1
2
7
.4
7
1
2
6
.5
5
1
2
5
.8
2
1
2
0
.9
5
4
0
.0
8
3
9
.8
7
3
9
.6
5
3
9
.4
5
3
9
.2
4
3
9
.0
3
3
8
.8
2
 
Figure 46.  13C NMR (100 MHz) spectrum of compound 4v’ in. CDCl3 + DMSO-d6. 
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Figure 47.  1H NMR (400 MHz) spectrum of compound 26w in CDCl3 
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Figure 48.  13C NMR (100 MHz) spectrum of compound 26w in CDCl3. 
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Figure 49.  1H NMR (400 MHz) spectrum of compound 26w’ in CDCl3 
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Figure 50.  13C NMR (100 MHz) spectrum of compound 26w’ in CDCl3. 
143 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
3.082.032.101.991.051.00
8
.3
4
8
.3
3
8
.3
1
7
.7
6
7
.6
6
7
.6
5
7
.6
4
7
.6
2
7
.4
8
7
.4
7
7
.4
5
7
.1
9
7
.1
7
7
.1
5
3
.7
2
 
Figure 51.  1H NMR (400 MHz) spectrum of compound 26x in CDCl3 
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Figure 52.  13C NMR (100 MHz) spectrum of compound 26x in CDCl3. 
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Figure 53.  1H NMR (400 MHz) spectrum of compound 26x’ in CDCl3 + DMSO-d6. 
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Figure 54.  13C NMR (100 MHz) spectrum of compound 26x’ in CDCl3 + DMSO-
d6. 
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Figure 55.  1H NMR (400 MHz) spectrum of compound 26y in CDCl3 
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Figure 56.  13C NMR (100 MHz) spectrum of compound 26y in CDCl3. 
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Figure 57.  1H NMR (400 MHz) spectrum of compound 26Z in CDCl3 
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Figure 58.  13C NMR (100 MHz) spectrum of compound 4y in CDCl3. 
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Figure 59.  1H NMR (400 MHz) spectrum of compound 26aa in CDCl3 
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Figure 60.  13C NMR (100 MHz) spectrum of compound 26aa in CDCl3. 
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2. A poster presentation titled “Copper-catalyzed intramolecular α-C‒H amination 
via ring-opening cyclization strategy to quinazolin-4-ones: development and 
application in Rutaecarpine synthesis” National Conference on Organic 
Molecules As Synthons and Reagents for Innovations (OMSRI-2019) held 
during February 8-10, 2019 organized by Department of chemistry, IIT 
Roorkee, I ndia. 
 
3. A poster presentation titled “Scaffold Diversity through a Branching Double 
Annulation Cascade Strategy: An Iminium Induced One-pot Synthesis of 
Diverse Fused Tetrahydroisoquinoline (THIQ) Scaffolds” March-2017, at In-
House Symposium, IIT Hyderabad, India.  
 
4. A poster presentation titled “Visible-Light-Mediated Nitrogen Incorporation via 
Dual C(sp3)-H and C(sp2)-H Bond Functionalization by Photo redox Catalysis” 
30th March-2019 In-House Symposium, IIT Hyderabad, India.  
 
 
 
